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recommends approaches to enhance visibility -within the public health commodities supply system of 
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Summary  
Personal work experience within the health commodities supply system of Ethiopia which is challenged 
by poor inventory management, inefficient tracking and tracing, fake or sub-standard medicines and 
bullwhip effect, and a later combination of those experiences with an academic study at Molde 
University College became my motivation to conduct this research study. Focusing on one of the supply 
chain actors; to find out where the challenges outlined above, to look at supply chain visibility and to 
explore approaches, I formulated research questions. Supply chain performance indicators, a 
quantitative model with case study and a case study with a supply chain visibility scorecard are applied 
to answer research questions 1, 2 and 3 respectively. 
 
What is the supply chain performance of the Ethiopian Public Health Commodities Supply System 
(EPHCSS)?  
For the sampled products, actors and within the measuring period, vital products availability ranges 
from 65% to 84.4%, against a 100% service level agreement. 75% of the commodities experienced 
stock-out for 1 to 4 times within the past 6 months of time for a duration of 10 to 147 days. Only 16-
50% of the products were stocked correctly where understocking being very likely. Forecast accuracy 
ranges from 0.22 to 2.59. 
Supplier fill rate is 100% in quantity and lead time is 1 month for two of the products. There is no 
computer to computer ordering system between actors and stock status monitoring is conducted 
monthly by all sampled hubs. 
 
How is Supply chain visibility implemented in the Ethiopian Public Health Commodities Supply 
System (EPHCSS)? 
In the inbound section, there is a better partial visibility (2.99/4) with regard to foreign suppliers of 
program pharmaceuticals than with the local suppliers (2.91) and international suppliers (2.79/4) of 
RDF pharmaceutical. In the outbound section, information flows in the program supply line have a 
better accessibility (above 75%) but with moderate quality; accuracy (2.44/4) and freshness (1.56/4) 
than the RDF supply line; accessibility (3.13/4), accuracy (2.21/4) and freshness (1.18/4).  
 
What are those approaches through which the supply chain visibility could be improved under the 
constraints of the EPHCSS? 
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GS1 data matrix barcoding with a unique serialization integrated with an inventory dashboard is one 
cost efficient approach recommended for the study system which would enable to easily track and trace 
products movement and offer data visibility as fresh and accurate as possible. Accurate, fresh and data 
rich inventory dashboard would enable decision makers to have a proactive approach therefore would 
trigger a better stock management. A unique serialization of products and an authorization at the time 
of receive and issue would block most possible ways of counterfeited and unauthorized medicines 
inflow.  
 
The responsible management body should take this urgent issue of product availability and low value 
of indicators to consideration for further wide analysis or appropriate measures. Diagnostic measures 
on the quality of data visibility should be taken. Further studies with adequate data to find out practices 
and experiences of program supply line over RDF supply line is advisable. In addition, to have a more 
detailed insight about the impacts of the recommended visibility approaches: it is recommendable to 
conduct a pilot project study. 
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1.0 Introduction  
 1.1 Motivation  
 
The advantage of having three years of personal working experience in the health care system of 
Ethiopia as a supply chain pharmacist and department head in a governmental pharmaceutical importer 
and wholesaler, PFSA, became a motivation for me to undergo this study. My position was in one of 
the 11 regional hubs studied in this thesis. The duty of the job was to manage the storage and distribution 
of pharmaceuticals that should pass through the hub to serve all health institutions within the hub’s 
radius which was in the southwestern region of Ethiopia.  
 
Through all this experiences, I have observed and became very familiar with common challenges that 
were frequent within the supply chain; 
 
 High and frequent Stock-out rate, leading to  
Shortage of (vital) health commodities, therapy discontinuation, death risk, good opportunity 
to drug resistance especially for the most dangerous cases in Tuberculosis and poor health 
service  
 Overstock inventory (mostly with a shorter shelf life and near expiry dates), leading to  
High rate of expiry, a risk to becoming expired and financial loss for an extra holding cost  
 Counterfeited commodities within the legitimate line, leading to   
Loss of lives, economic impact and loss of trust on the public health  
 Hectic and manually laborious commodity tracing system during a product recall leading to  
   Inefficient tracking and tracing of all the required items belonging to the batch recalled and a 
non-speedy system allowing some of those items to already be used   
 
Figuring out and being involved in those challenges was my head ache and triggered my alertness to 
find out where truly the challenges are, and further to explore approaches to intervene the challenges. 
 
Since the time I joined the academic study in Molde University College, the studies I took and 
indications/ suggestions from professors gave me the insight and became a real motivation for me to 
take this topic as my MSc research.  
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 1.2 Research Questions  
 
To find out where the challenges outlined above, I formulated research question 1 as: 
  What is the supply chain performance of the Ethiopian Public Health Commodities Supply System 
(EPHCSS)?  
In the three-tier supply chain, one of the key players and central body in the EPHCSS is the 
pharmaceuticals fund and supply agency (PFSA) which has the responsibility of quantification, 
procurement, inventory management and distribution of pharmaceuticals within Ethiopia. It is the focal 
company within EPHCSS.  
 
There are so far very few scientific studies conducted which focused specifically on PFSA supply chain 
challenges mentioned above. The ones that exists are informal and non-recent. Therefore, studying the 
supply chain performance of the focal company by applying key supply chain performance indicators, 
will give a scientific perspective about the significance of the challenges and an indication about the 
activities or processes to target in an intervention.  
 
The supply chain performance indicators used to answer research question 1 are indicators measuring 
operational performance, e.g. like stock-out rate and order fulfillment rate. The operational 
performance in turn depends on a range of environmental and infrastructure factors like business 
environment, governmental regulations and technological infrastructure. The current situation for 
Ethiopia regarding such broad factors is briefly described in the thesis.  
 
As a key motivation is to explore approaches to improve supply chain performance, I have looked for 
measures that can tell where to put the focus.  
Supply chain visibility is rated as the most important measure for supply chain performance both by 
business leaders and researchers, (McIntire 2014).Therefore I decided to look at supply chain visibility 
in particular by formulating research question 2. 
 
 How is Supply Chain Visibility implemented in EPHCSS? 
Efficient supply chain visibility is one of the priority qualities required to have in a supply chain to 
counteract bullwhip effect, inefficient tracing and tracking and counterfeit medicines. There had not 
been any supply chain visibility studies so far conducted in the study system. Being able to know the 
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current inbound and outbound supply chain visibility status of the focal system is therefore a key 
element to base future benchmarking and undergo diagnostic measures more easily in the areas where 
a visibility improvement is more urgent.  
Lastly, to explore approaches to improve supply chain performance, I focus on supply chain visibility 
aspects. Research question 3 is: 
 What are those approaches through which the supply chain visibility could be improved under the 
constraints of the EPHCSS? 
There are different kind of solutions and approaches in use to enhancing supply chain visibility. Having 
the fact that, supply chain visibility boosts the power of a company in fighting the supply chain 
challenges, research question three, analyzes points and possibilities of improvement within EPHCSS, 
and recommends approaches, which could enhance the visibility and thereby the supply chain 
performance.  
1.3 Literature reviews  
 
Supply chain performance  
There are several studies done about the health commodities supply chain performance of the EPHCSS 
where most of the studies focused only on health facilities, one integral part of the health 
system(Berhanemeskel 2014, Shewarega et al. 2015, Sinishaw et al. 2015, Tessema and Amene 2012, 
Biruk et al. 2014). Even if the performance study on health facilities has an implication about the whole 
system, there are so far very few and limited scientific supply chain performance studies focusing on 
PFSA.  
 
Two recent studies made to assess the health commodities supply chain management in selected public 
health institutions in Ethiopia shows: Lack of adequate supply of products, frequent stock-outs, frequent 
emergency order of drugs, understocking, significant variation in availability of key medicines and 
poor supply performance of importers, (MoH 2015 , Berhanemeskel 2014). 
 
An Ethiopian national survey indicates poor order fill rate (the percentage of items that are filled, based 
on the ordered quantities with the correct products) to health institutions, shortages of products at 
central level, and product overstocking , (Shewarega et al. 2015).  
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A research study to assess the distribution and availability of essential tuberculosis diagnostic items in 
eighty health institutions in Ethiopia show ineffective distribution due to complete stock out of products 
which challenged sustainable supply of tuberculosis laboratory reagents ,associated with weak 
tuberculosis diagnostic and follow up services which latter triggered reluctance of health personnel at 
all levels not to make ordinary product requests,  (Sinishaw et al. 2015).   
 
An Ethiopian situational assessment shows significant challenges within PFSA in record-keeping, 
forecasted data quality, timely requisition and consumption reporting. Wastage of pharmaceuticals due 
to expiry, theft, and damage were found. Huge gaps in recording and documentation of pharmaceuticals 
that are unfit for use at health facilities were also documented, (MoH 2015 ). 
 
A comparative quality evaluation study for marketed medicines indicated the existence of counterfeit 
medicines within the legitimate supply chain,(Sahle et al. 2012). Another nationwide survey also gave 
a highlight of how prevalent substandard products are fed into the supply system of Ethiopia, (Suleman 
et al. 2014). This survey which assessed the quality of medicines evidenced the high prevalence of poor 
quality drugs within the supply chain. The clear limitations in safety and quality assessment for 
medicines prior to their entry to market and poor post-marketing surveillance are another batch of 
logistic risks which resulted in loss of trust by the public as shown by national assessment study,(MoH 
2015 ).  
 
The reviewed literature studies clearly show that it is a high time for the Ethiopian health care supply 
chain to put into effect an intervention mechanism to the versatile challenges they are experiencing 
which is impeding the health care delivery and consequently the health of the population.   
 
Supply chain visibility  
Supply chain visibility studies are totally new to EPHCSS. I could not find any scientific studies 
conducted so far on the study group. However, International studies focusing on the different benefits 
of supply chain visibility, ways of measuring, and improvement approaches are multiple.  
 
Supply chain visibility in a wide perspective is defined as the ability of a focal company and actors 
within a supply chain to access, share, capture, integrate, create intelligence of/from a key, useful or 
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important information or that information readily availability for monitoring, controlling, changing or 
decision making purposes, (Caridi et al. 2014, Barratt and Oke 2007, Francis 2008., McIntire 2014 , 
Musa, Gunasekaran, and Yusuf 2014).  
 
Several researches and case studies indicate that supply chain visibility improve company performance: 
by supporting the decision-making process. Supply chain visibility increases information availability 
and accuracy therefore making the supply chain responsive, reliable and flexible. One way or the other, 
the common supply challenges are a direct result of poor visibility or decision making made on 
inaccurate/out-of-date data, (Caridi et al. 2014, Barratt and Oke 2007, Musa, Gunasekaran, and Yusuf 
2014, Schoenthaler 2003, Wang, G., and Wei 2007).   
 
Supply chain visibility increases demand visibility between members of the supply chain. How well 
demand forecasts can be improved depends on how visible the underlying demand actually is. Demand 
visibility here refers to the ability to see undistorted and accurate demand within the timeframe 
necessary to react to it, (Schrieber and Jared 2005). The more visible the demand, the greater the 
likelihood of accurate demand forecasts. Most retailers do not know their demand with certainty, they 
make their inventory decisions based on demand forecasts. When the forecast is not very accurate, the 
quantity they order does not reflect the demand for the periods that the ordered quantity is supposed to 
cover. The errors in the retailer’s forecasts are passed to the supplier in the form of distorted orders: 
bullwhip effect. By appropriately sharing accurate information between suppliers and retailers and 
coordinating replenishment and production decisions under demand uncertainty, suppliers are able to 
smooth the peaks and the valleys in the flow of goods : to reduce the bullwhip effect. Studies show that 
solutions like vendor managed inventory (VMI) which enhance visibility reduce bullwhip effect by 
50 %,(Marqués et al. 2010. ). 
 
Cost optimization (production, logistics and transportation costs), effective distribution of inventory, 
efficient service levels, product availability, accurate demand forecasting, efficient tracking and 
tracing, product authentication  are few of the main benefits of a successful supply chain visibility, 
(Zhao et al. 2002, Yao, Yuliang, and Dresner 2008, Ryu, Tsukishima, and Onari 2009).  
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Therefore, for any supply chain system which aspires to improve its handling of supply chain 
challenges associated with poor inventory management, tracking and tracing inefficiencies and entry 
of fake products, have enhancing the supply chain visibility as a prime objective.  
 
There are so far no supply chain visibility studies conducted on EPHCSS to benchmark and baseline a 
recommendation solution. This study will show how supply chain visibility is currently implemented 
in EPHCSS.  From the review of literatures, it can be seen that, visibility can be measured from different 
perspectives and assumptions. While measuring, supply chain visibility is considered to influence the 
supply chain operation, which in turn influence the business outcomes, (McIntire 2014 , Caridi et al. 
2010a). 
 
1.4 Country context and study system  
 
Ethiopia, located in the North East part of Africa is the oldest independent and second most populous 
(96 million) country in Africa. It served as a symbol of African independence throughout the colonial 
period, and was a founding member of the United Nations and the African base for many international 
organizations, (Bank 2016 , Wikipedia 2016). 
 
As of 2015, there are a cumulative number of 311 hospitals (including private), 3,547 health centers 
and 16,440 health posts available. About half of health facilities have regular electricity or has 
functional generator with fuel. About 88-100% of hospitals (public & private), 57% health centers and 
29% of health posts have regular power sources. Information communication technology development 
in the health sector focused on tele-education, tele-medicine, electronic health management information 
system (eHMIS) and electronic medical records (EMR). Health technology management, including 
medical equipment maintenance, are among areas that are in focus by the national health sector 
development plan (HSDP) of Ethiopia, (MoH 2015 ).  
 
FMHACA (Food, Medicine and Health Care Administration and Control Authority), a sub-ordinate of 
the Ministry of Health, is the authority given the mandate of food and pharmaceuticals regulation. 
FMHACA owns the national quality control laboratory, which is equipped with different testing and 
analyzing devices to undergo physicochemical tests. It also updates each year the list of national 
medicines, (FMHACA 2013 ).  
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The Ethiopian Public Health Commodities Supply System (EPHCSS)  
The Pharmaceutical Supply Chain (PSC) is ‘‘the integration of all activities associated with the flow 
and transformation of drugs from raw materials through to the end user, as well as associated 
information flows, through improved supply chain relationships to achieve a sustainable competitive 
advantage’’(Uthayakumar and Priyan 2013) 
 
The pharmaceutical supply chain is unique compared to other supply chains. First, anything less than 
a customer service level of 100% is unacceptable because of the direct impact on health and safety. 
Ensuring a 100% product availability at a feasible cost represents a huge challenge requiring the supply 
chain processes to be streamlined towards customer demands. Second, product perishability is another 
critical issue. Outdated or expired items may be overlooked and dispensed to patients, which could 
have potentially disastrous effects on both patient care and public relations. Third, complexity of the 
network system and strict regulations is quite big. Fourth, the pharmaceuticals require special storage 
and transportation conditions like cold room storage system(2-8oc), deep freeze storage system (< 0oc) 
and sun-light protected storage area, (Whewell 2012). 
 
The Ethiopian public health commodities supply system (EPHCSS) mainly comprises of three major 
players: producers, purchasers, and pharmaceutical providers. The EPHCSS constitutes; 
Manufacturers/Importers, Wholesalers(National/Regional), and health facilities as core actors 
(PFSA,2015).  
 
 
 
 
 
 
 
 
There are 257 private importers /wholesalers and 1 public importer/wholesaler (with 11 regional hubs 
) as of 2014 all over the country, (FMHACA 2014 ). 
 
Local 
manufacturers  
Importers 
International 
manufacturers  
Wholesalers 
Health 
facilities  
 
 
 
 
 
 
 
                                                                                                                        Source: Own work 
 Figure 2; Main Skeleton of the EHCSS supply chain 
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As of 2010, the country’s national drug list has 1189 pharmaceutical product groups, which can be 
imported or locally produced subject to compliance with the registration requirements of the authority. 
877 suppliers (both local and international) supply those product groups; 854 of the products are anti-
retroviral therapy class products and agents, 8 anti-malarial product class and 327 are other class. Local 
manufacturers covers 20% demand of the country’s pharmaceutical need, (FMHACA 2013 , MoH 
2015 ). 
 
The government of Ethiopia has established an agency named PFSA - the Pharmaceuticals Fund and 
Supply Agency- an autonomous federal organ having its own legal personality with the purpose of  
guaranteeing a continuous supply of quality assured essential medicines, at an affordable price to public 
health facilities, (PFSA 2014 ).  
 
PFSA – (Pharmaceuticals Fund and Supply Agency), (PFSA 2015, MoH 2015 , PFSA 2014 )  
PFSA is the focal company of focus in this study, which is a sole government organization handling 
distribution of health commodities to the public health institutions. It handles forecasting, procurement, 
storage, distribution and rational use of drugs. Securing 100 percent availability and continuous supply 
of vital health commodities is the primary goal of the service level agreement (SLA) of the agency. It 
procures pharmaceuticals from local and international manufacturers, stores in its central hub and 
distributes it to 11 hubs (red dots on the map) and 7 sub-hubs (blue dots) dispersed geographically 
proximal to health facilities. Moreover, from the regional hubs goes down to health facilities where the 
end customer gets the commodities.  
 
 
 
 
 
 
 
 
 
 
Source:(PFSA,2015) 
 
 
Figure 3; Geographic locations of PFSA Regional Branches (Hubs) 
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The Agency’s annual distribution capacity has increased from 2.74 Billion ETB1 in 2011 to 12.10 
Billion ETB in 2015. Seventeen modern warehouses are completed which raised the national storage 
capacity from 46,260 m3 to 531,000 m3 and the cold chain storage capacity from 50 m3 to 800 m3. 
PFSA has seven directorate departments (figure 6) with unique job responsibilities: Forecasting and 
Capacity building, Storage and distribution, Fund management, Pharmaceuticals and Medical Supplies 
Procurement, Human Resource & General Service and Planning/MIS and Public relations office.  
 
 
 
            
 
 
 
 
 
 
 
                                                                                               Source: Own work  
As an agency with a prime responsibility of managing the pharmaceutical logistics system of the 
country, PFSA has indispensable roles and responsibilities (Annex 6.4).  
 
The health commodities, which PFSA is providing to the public health institutions, are majorly of two 
categories: Free (Program) and Purchase (RDF-Revolving Drug Fund).  
 
The Program group constitutes; drugs, reagents and medical supplies related to ART (Anti-Retroviral 
Therapy), TB/Leprosy, Family Planning, Malaria, and Infection Prevention. The government, global 
donors and other stakeholders are key players within the supply chain of program pharmaceuticals in 
donating to the purchase of the items, infrastructure and capacity building.  
 
                                                 
1 1 ETB = 0.046 USD (http://www.xe.com/currencyconverter/convert/?Amount=1&From=USD&To=ETB)  
Figure 4; Organizational department setup of PFSA 
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The RDF group constitutes; drugs, reagents and medical supplies related to any vital, essential and non-
essential list of items. They are not specifically bought for a given treatment groups, but for a general 
use based on the national drug list as per the need of facilities They are served with a 20% or 30% of 
marginal profit to the public and the profit is revolved to purchase another quantified and forecasted 
need of items in a new budget year.  
 
The supply and distribution of pharmaceuticals are done using an integrated information system; 
Integrated Pharmaceutical Logistic System (IPLS)(Annex 6.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improving visibility along the Pharmaceutical supply chain: A case study on EPHCSS 
 
Master Thesis                                                                           Molde University College  11 
2.0 Research Methodology, research design, data collection  
2.1 Research methodology  
2.1.1 Research question 1 methodologies; 
2.1.1.1 Methodology one;  
To measure the supply chain performance of the system, specifically of the focal company, six key 
supply chain performance indicators, which have a link with the research challenges are selected from 
a guide prepared by USAid, (Aronovich et al. May 2010).  
Though the guide enables to measure up to a total of seventy (70) indicators segregated in function and 
four indicators (Annex 6.6), but for the following key reasons seven were selected to be used for this 
research study.  
1) Theme and purpose of the research study; the findings of those selected indicators shall indicate the 
significance and weight of the research problems and could be taken as an input while making 
recommendation to the other part of this study. Therefore, only those indicators which are believed 
to have a link with the research problems, visibility and the theme of this research topic are selected.  
 
2) Limited time for data collection; especially from a system where many procedures are done 
manually and where paper data tracking may become a mandatory part of the job, getting data for 
all the 70 indicators would require and consume a great amount of time beyond what is scheduled 
and allocated in the time table for this research study.  
 
Therefore, for this research project; a total of eight (7) indicators with 3 indicators of quality (from the 
inventory management and product forecasting function group), 1 indicator of response time (from the 
inventory management function) and 3 indicators of productivity (from the inventory management, 
sourcing and procurement function) were selected.  
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Table 1; Supply chain performance indicators along with the logistics functions they target 
  
Supply chain/logistics functions 
                                                      Indicators  
Quality  Response time  Productivity  
Inventory management/LMIS/  
customer response  
1. Stock out rate  
2. Plan in place for 
predictable 
change in 
demand  
 
3. Order Lead 
time  
4. Percentage of 
orders placed 
through 
electronic 
ordering system  
Supplier/Sourcing (from purchasers 
perspective)  
  5. Supplier Fill 
rate  
Product 
selection/Forecasting/Procurement 
6. Forecast 
accuracy error  
 7. % of purchase 
orders /contracts 
issued as 
emergency 
orders  
 
2.1.1.2 Methodology two;  
Two of the research problems are in and around the area of product availability. Therefore, a product 
availability survey for six (6) regional hubs is conducted for a basket of sixteen (16) vital 
pharmaceuticals; 11 RDF and 5 Program. As the product availability survey questionnaire table (Annex 
7.9) has previously been used to conduct a national survey at health facilities level, there was no need 
of conducting a pilot study prior to using it.  
2.1.2 Research question 2 methodology;  
A quantitative model enabling to measure the visibility level in complex supply networks, from an 
inbound and outbound side with an ambition targeting on benchmarking and diagnostic purpose is 
applied, (Maria Caridi 2010). 
Therefore while using the model, structured approaches were followed to assess the visibility of the 
focal company –PFSA-has of its supply chain. Doing that, instrumental steps were ensued to reach 
the final goal (Annex 6.6). 
Source : (Aronovich et al. May 2010) 
Improving visibility along the Pharmaceutical supply chain: A case study on EPHCSS 
 
Master Thesis                                                                           Molde University College  13 
2.1.3 Research question 3 methodologies:  
2.1.3.1 Methodology one;  
To get a deep insight of the system, especially the whole process and activities in and around the focal 
company, a case study methodology is followed. The case is studied with an intrinsic interest focusing 
on understanding the EPHCSS, mainly the work flow of the focal company. Triangulation provided an 
important way of ensuring the validity of the data; previous work experience, standard operating 
procedures and interviews.  
2.1.3.2 Methodology two: 
A qualitative and quantitative approach/score-carding technique is used to assess effectiveness of the 
recommended improvement approaches. The approach has its own metrics and methodology referred 
to as the “supply chain visibility scorecard”, and it represent an approach to measuring the performance 
of supply chain visibility directly without conflating the metrics with the impact visibility is having on 
the overall supply chain operation. The scorecard is decomposed in to four primary metrics which 
directly reflect on the performance of the four steps within supply chain visibility (Annex 8.0), 
(McIntire 2014). 
2.2 Research design  
2.2.1 Research question 1 design  
2.2.1.1 Method 1;  
Values for the formula variables are grabbed for three product lines; 1 pharmaceutical product from 
each; RDF, Program International suppliers and RDF local suppliers.  
List of variables where their values (recent data) gathered;  
 Forecasted consumption 
 Actual consumption 
 Total number of orders placed for the product  
 Number of emergency orders made on the product  
 Total quantity ordered (for the product) 
 Number of order lines/SKUs/ shipped in initial shipment (for the product) 
 Total number of hubs that are expected to offer that product  
 Number of hubs that experienced a stock-out of a specific product  
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 List of plans in place to respond to seasonal variance in demand  
 Total number of orders placed  
 Sum of the number of days between when orders were placed and when orders were received  
 Number of orders placed through electronic system  
  
2.2.1.2 Method 2;  
For the list of products identified as fast-moving, vital and high consumption, a product availability 
survey table constituting data input columns were filled by six PFSA regional hub pharmacists working 
in the supply chain unit. 
2.2.2 Research question 2 design;  
To make the study specific, suppliers of vital, high-consumption and fast moving products from the 
context of the country, are part of this study.   
The kind of information flows that exchanged within the selected pharmaceutical suppliers and 
hospitals is collected and categorized into the four types of information flows. Local suppliers, 
international suppliers of program pharmaceuticals and international suppliers of RDF pharmaceuticals 
are the three key groups of suppliers. While Black Lion hospital, Alert hospital and Emmanuel hospital 
are the three key health institutions.   
How much (quantity) of the information flows exchanged within pharmaceutical suppliers and health 
institutions does the focal company accesses and of in what quality (accuracy and freshness) is 
quantified and graded in scale of 1-4 based on the ranking system offered by the methodology(Annex 
8.0).  
2.2.3 Research question 3 design;  
First, reasons for insufficient supply chain visibility are identified leading to possible areas for 
improvement. Second, a time series analysis of chronological sequence is done. Third, based on the 
insights from the case study, a process model is designed coherent of the individual supply chain 
process steps and actors of the system. Fourth, based on the process model, unused potentials of 
visibility were identified. Fifth, in addition, to that, key points which are certainly critical for the 
creation of the research problems are identified. Sixth, based on the insight of the case study, references 
of similar projects, cases from the literature and my advisors personal expertise; improvement 
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recommendations were suggested. Seventh, and finally, those improvement recommendations were 
analyzed for a fitness of relevance. 
2.3 Data collection  
The time period of the data collection with the kind of activity held is summarized in table two. 
Generally; interviews, focus group discussions, email surveys, questionnaires, firm entity visits, data 
analysis were key data gathering methods used.  
Table 2; Data collection: type of collection method, theme and time frame 
 Type Theme (Activity) Time period 
RSQ1 1. Discussion  and interviews with 
PFSA FCB unit (Appointment in 
person) 
Key 1; To collect the variables for 
the index; the seven supply chain 
performance metrics  
 
February 4- March 1 
2. Data Analysis (Records, 
archives, SOP’s) 
1. Survey tables spread to 11 main 
regional hubs through an email 
communication (> 3 times), and six 
replied during the time frame of the 
data collection  
Key 2; Product availability table 
to assess stock-outs and 
overstock,  
March 20 
RSQ2 1. Discussions and interviews(based 
on semi-structured questionnaires) 
with local pharmaceutical 
manufacturing company 
representatives; Julphar, Cadilla, 
APF, Epharm  
 
Key 3; Needed for the approach-
to build the product process flow 
within pharmaceutical suppliers  
 
Key 4; From that to find out what 
information the international 
suppliers exchange on those 
products they supply to PFSA  
February 4- March 1           
2. Email communications and 
website material access for 
international suppliers: Auro bindo 
Pharma Limited, Macleods ,San 
,Strides ,  Arcolab , 
GlaxoSmithKline (GSK), 
Egyptian International EIPICO, 
Gulf Pharmaceuticals, 
Huanggang Hyangzhou, Truskin 
Glove Pvt.Ltd, Vins Biopoducts 
Ltd, CSPC Zhongnuo 
Pharmaceutical 
1. Discussion and interview with 
PFSA general director  
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2. Discussion and interviews with 
selected hospital pharmacy heads 
(BLH, Emmanuel, Alert hospital -
appointment in person) 
Key 5; Needed for the approach-
to build the product process flow 
and activity flows  within health 
institutions  
 
Key 6; From that to find out what 
information the institutions 
exchange on those products they 
are supplied by PFSA  
 
1. Discussion and semi-structured 
interviews with PFSA FCB unit ( 
Directorate director, coordinator, 
officers- appointment in person) 
Key 7; Needed for the approach – 
to mark how and what or which 
of the information the 
international suppliers/health 
institutions exchange does this 
core company access/share   
1. Data Analysis of financial 
documents(yearly purchase 
amounts, hub consumption reports) 
 
Key 8; Needed for the approach- 
to select and grade those 
pharmaceuticals focused for this 
research and to grade the 
suppliers significance with respect 
to the hub  
 
RSQ3 
1. Focus group discussions with 
FCB and SD team, 
2. Rigorous interviews,  
3. Site visit  
4. Data analysis from department 
SOP’s, analysis of case studies and 
literature reviews 
 
Key 9; To draw the process map 
of the core company and to study 
and recommend similar 
improvement approaches 
February 4- March 1 
 
 
Source: Own work  
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3.0 Data Analysis and discussion  
3.1 Part I- Supply chain performance  
3.1.1 Section-I-Supply chain performance indicators 
The data collection is done based on three products; one product from the RDF/International 
suppliers (Chloramphenicol Sodium Succinate 1gm injection), one product from RDF/local 
suppliers (Amoxicillin 500mg capsule) and one product from program category (Lamivudine 
300mg/Tenofovir 300mg/Efavirenz 600mg). Highest consumption and vital products are selected. 
Measurement procedures indicated by the guideline were followed (Annex 6.7) to come up with 
the following results.  
Table 3; Summary of supply chain performance indicators 
  Performance indicators 
Produc
t  
group  
Sample 
pharmaceu
ticals 
Stoc
k-
out 
rate
s 
(%) 
Order 
lead 
time(mo
nth) 
Suppl
ier 
fill 
rate(
%) 
Forecast 
accuracy
error 
Percentage 
of 
purchase 
orders/cont
racts 
issued as 
emergency 
orders 
Plan in 
place for 
predictab
le 
change 
in 
demand 
Percent
age of 
orders 
placed 
through 
electro
nic 
orderin
g 
system 
RDF/IN
T 
CAF inj 
 
36.3 > 1  100 2.59 0 Monthly 
stock 
status 
monitori
ng is 
impleme
nted in 
all hubs  
 
None 
 RDF/L
OC 
Amox 500 
 
0 1  1002 0.25 0 
PROG/
INT 
3TC/TDF/E
FV-adult 
 
27.2 3  100 0.22 20% 
 
 
 
 
 
 
                                                 
2 Special Condition  
Improving visibility along the Pharmaceutical supply chain: A case study on EPHCSS 
 
Master Thesis                                                                           Molde University College  18 
Research question 1: 
 What is the supply chain performance of EPHCSS?  
As mentioned on the motivational part of this study, the studies so far available concerning the 
health care supply chain performance of Ethiopia targeted only two of the actors within the system; 
health facilities (hospitals, health centers and health posts) and suppliers. PFSA, which is the main 
role player in the public health supply chain of Ethiopia, has not been the main target of such 
similar studies so far .Facilities stock status , product availability and every other health 
commodities logistics issues and risks are directly dependent on the performance of PFSA. At the 
same time, every communication of suppliers with health facilities is through PFSA, strengthening 
the vitality of PFSA in the health care supply chain.  Even-though the main target of this study is 
mainly visibility, recommendation of improvement approaches, but the paper also aims to give an 
insight about the supply chain performance of PFSA no matter the measurements, and sample used 
are limited. Limited measurements are better than no measurements/data, as they give at least some 
insight in the characteristics of EPHCSS. 
 
Stock-out rate of the focal company ranged from 0% to 36.3%. The focal company experienced 
no stock out in its hubs during the whole year of 2015 for the locally supplied product, while three 
of the hubs experienced stock-out for the internationally supplied program product and four of the 
hubs for the internationally supplied RDF product. As a direct implication of this, 20% of the 
orders for the program drug were issued as an emergency order, while there were no emergency 
orders within the year for the locally supplied product. It may seem counterintuitive not finding 
any emergency orders made during the year for the internationally supplied RDF product. Forecast 
accuracy error as per MAPE (mean average percentage error) is 2.59, 0.25 and 0.22 for the 
internationally produced RDF, locally produced and internationally produced program products 
respectively. High amount forecasted but less amount consumed, but confusingly high stock-out 
rate of 36.3% and no emergency orders. Deep investigation on this result shows that, the 
distribution was poor making those hubs who had the product in an overstocked level which later 
was recognized so that a branch to branch transfer done avoiding the emergency ordering. Even if 
the data it is based is limited, but the sample scenario shows poor forecast efficiency and 
distribution rationing which probably created overstock inventory in some hubs and stock-outs in 
others.  
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All the three suppliers’ capacity of supplying the exact amount and on the exact date specified on 
the contract was 100%, which takes away the burden of blaming the suppliers for stock problem 
by the focal company for three of the sample products for the measurement year. The average lead-
time for the program supplier is 3 months. While 1 month for the local supplier and none of the 
orders have physically arrived for the selected product by the RDF international supplier.  
 
For all the three products, orders from focal company to suppliers is fully non electronic ordering 
system referring to an electronic ordering system as an IT-system used while conducting a 
purchase or an order, for direct communication with the supplier’s IT-system with no humans 
involved. Email, phone, fax, or other electronic communication means’s are not official and 
primary use, rather a letter ordering system, which the focal company uses.  
Likewise the focal company-supplier relationships, the health institutions main means of 
communication in product ordering is also in paper format called RRF (Report and requisition 
format) which has to be filled and sent through a mail or delivered in person.  
The only plan available for managing a predictable change in demand by the focal company is a 
monthly stock-status monitoring scheme by the FCB department. All eleven hubs (which normally 
represent the focal company-PFSA) complete a report of “warehouse stock status in quantity” 
which is a reconciled data from HCMIS and paper bin-card, every month. Such a long time to 
assess stock-status of hubs (poor quality of internal visibility of stock-status) probably is one 
factor, which creates poor intervention towards overstock inventory, especially for products with 
near expiry dates.  
3.1.2 Section-II, Product availability  
The most important output of a logistics system is stock availability since it will improve health 
outcomes. Unavailability in any health system is considered a critical system failure since stock-
outs can result in patients going without life-saving pharmaceuticals. An additional effect is the 
reduced confidence in the health system. Even where stock-outs are rare, hubs with too little stock 
at the time of the survey are either likely to stock-out or will require an emergency order before 
they receive their next routine order; while overstocks can mean waste and 
inefficiency,(Shewarega et al. 2015).  
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To assess stock availability at PFSA hubs, the questionnaire collected data on stock on hand, 
frequency and duration of stock-outs on the day of survey and during the six months prior to the 
survey for six (6) PFSA hubs.  
 
Stock-out data this time is directly collected from the hubs for the instant time of the data collection 
period and for the six months of time prior to the data collection. However, at section-I, the annual 
report of the forecasting and capacity building department is reviewed. Therefore, this measure 
offers a more updated and accurate data.  
 
3.1.2.1 Availability on day of visit (Annex 6.8)  
 
Overall, the majority of the PFSA hubs had most of the essential pharmaceuticals in stock on the 
day of the data survey: average availability is 84.4 percent for the basket of commodities, for six 
regional PFSA hubs. Of the 16 items assessed, availability is 100 percent for 8 items, 83.3 percent 
for four items, 66.7 % for three items and 16.7 % for one item. 
 
Products with 100 percent availability at regional hubs are (4 out of the 11 RDF products and 4 
out of the 5 program products) Nifedipine, Erytromycin, Gauze Surgical, Amoxicillin, 
3TC/TDF/EFZ, AZT/3TC/NVP, RHZE and Co-artem. Overall, availability of (3 RDF and 1 
Program) CAF, Cimetidine inj, Cotrimoxazole suspension and Depo is good (83.3%). 
Ciprofloxacin, TAT and Insulin suspension (all three from the RDF category) availability is low 
at 66.7% and surgical glove (RDF product) being only available in one hub.  
3.1.2.2 Availability within last six months (Annex 6.9)  
 
Data is also collected on the availability of the selected products throughout the six-months prior to 
the assessment—how many times hubs had stocked out and for how many days. This information is 
useful in determining whether hubs chronically or intermittently stock-out. Data are collected by 
reviewing the HCMIS (Health Commodities Management Information System) and bin cards; not on 
a physical inventory. Bin-cards at PFSA are paper formats of stock control that are used to register, 
receive and issue of items with a current balancing record. HCMIS in the other hand is an electronical 
way of doing receive and issue records, (Annex 6.3). Therefore, for the selected products, the past 
progress history on the records is reviewed to find out the number of times and the duration of days 
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the record reading had been zero. Therefore, the accuracy of the indicator relies on the hubs 
recordkeeping.  
 
The average stock availability in the past 6 months is 66.67%. Availability of four products during 
the past six months is 100% (3 from the Program and 1 RDF locally supplied), 83.3% for four 
products, 66.67 % for three products, 50% for one product, 33.3% for one product and 16.67 % 
for three products. During the last six months, all the program products included in this study 
except depo-provera and RHZE are the most available products at the hubs—with a 100% of 
availability.  
Stock-outs for gauze surgical, TAT, Cimetidine,(all three from the RDF category) are high 
compared to other products, with a stock-out of atleast once in four of the hubs in the six months 
prior to the survey.  
3.1.2.3 Frequency of stock-outs  
 
In hubs that had a stock-out of a product at least once in the six months prior to the survey, the 
survey assessed the number of times a stock-out occurred. The frequency of stock-out is from a 
range of once to four times average. Stock-outs of Insulin, Cimetidine and cotrimoxazole 
suspension (all RDF) is more frequent: they occurred, on average 4.6, 3.4 and 3 times, respectively. 
Frequency of stock-outs is lower for CAF, Erythromycin, Nifedipine, Ciprofloxacin, and Depo-
Provera (three Program and one RDF).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5; Frequency of stock-outs within the last six months prior to the survey 
by hub type, April 2016 
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3.1.2.4 Duration of stock-outs  
 
The average duration of stock-outs varied widely among the products, ranging from 10 to 147 
days. The duration for erythromycin, cimetidine, TAT, cotri-moxazole suspension and insulin (all 
from the RDF category) is the highest; being an average of 147, 109, 77, 58 and 48 days 
respectively. While stock-outs of RHZE and Depo-provera (the two products from program line) 
being 16.5 and 16 days respectively.  
 
Figure 6; Duration of stock-outs within the last six months prior to the survey by hub type, April 
2016 
 
 
3.1.2.5 Stock on hand (months of stock)  
 
IPLS (Integrated Pharmaceutical Logistic System) introduced minimum and maximum inventory 
levels for the regional hubs. Regional hubs have a minimum inventory of two months of stock and 
a maximum of four months. Proper commodity management ensure that inventory levels remain 
within this set range, (PFSA 2015). 
Using issues data to assess a hub’s stock status, the average monthly consumption (AMC) is 
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hand or physical inventory count is divided by AMC to determine how many months of stock were 
available.  
The result presented in figure 23.0, shows that most hubs are not stocked according to the 
recommended two to four months of stock. The percentage of hubs stocked correctly ranges 
between none of the hubs stocked correctly for products- (3 RDF and 1 Program) surgical glove, 
cimetidine, ciprofloxacin and RHZE and 83 percent for Nifedipine (RDF). For most products, only 
between 16-50 percent of hubs are stocked correctly. In most of the products assessed, 
understocking is more likely than overstocking. Most hubs are not stocked accordingly to the 
inventory policy of the agency: to hold a minimum stock of 2 times the AMC (Average Monthly 
Consumption) and a maximum stock of 4 times the AMC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7; vital medicine stock on hand on the day of visit by product, April 2016 
 
Nife
dipin
e
20m
g
table
t
Insul
in
zinc
susp
ensi
on
100I
U/ml
inj…
Chlo
ram
phen
icol
Sodi
um
Succi
nate
1g…
Eryt
hro
myci
n (as
Stear
ate)
table
t -
25…
Gauz
e
Surgi
cal
90c
mx1
00 m
mes
h…
Surgi
cal
glov
es
steril
e
latex
No.
7.5
T.A.T
.
1500
IU/m
l
injec
tion
Cime
tidin
e
200
mg/
ml,
2ml
injec
tion
Cotri
mox
azol
Susp
ensi
on
240
mg/
5ml
Amo
xicilli
n
250
mg,5
00m
g
table
t
Cipr
oflox
acin
500
mg
Tabl
et
Lami
vudi
ne
300
mg/
Teno
fovir
300
mg…
Zido
vudi
ne
300
mg/L
amiv
udin
e
15…
RHZE
(150
mg+
75m
g+40
0mg
+275
mg) ,
RH…
Arte
met
her +
lume
fant
hrin
e (
20
+1…
Med
roxy
prog
ester
one
acet
ate
150
mg…
More than 4 months(Overstocked) 1 0 2 3 0 0 1 1 1 3 2 0 1 1 2 1
2-4 months(Stocked Correctly) 5 1 2 2 1 0 1 0 2 1 0 1 2 0 3 1
Less than 2 months(Understocked) 0 3 1 0 4 2 2 4 2 2 2 5 3 5 1 3
0
1
2
3
4
5
6
7
Minimum and Maximum Inventory Levels 
Less than 2 months(Understocked) 2-4 months(Stocked Correctly) More than 4 months(Overstocked)
Improving visibility along the Pharmaceutical supply chain: A case study on EPHCSS 
 
Master Thesis                                                                           Molde University College  24 
Figure 8; Stock availability performance measures -RDF versus Program 
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pattern, program drugs are with better availability than RDF products for the past six months. The 
service level agreement of the focal company, PFSA, is to avail a 100% availability of products to 
the public(PFSA 2015). Unavailability of such vital products from any of the focal company hubs 
is therefore a critical issue to be considered and one indication of deviation from ultimate 
objectives of the hub that requires an immediate intervention.  
In hubs that had a stock-out of a product at least once in the 6 months prior to the survey, the 
frequency of stock-out is from a range of one to four times in average. Stock-outs of 3 RDF 
products is very common with a frequency of 3 to 4.6 times. The frequency of program drugs 
stock-out is relatively lower. An average frequency of stock out for program and RDF products is 
1.5 and 2 times respectively.  
78.7
56.05
2.01
55.51
27.35
96.6
90
1.515.75
24
Immediate Stock availability
Stock availability last 6 months
Frequency of stock-outsduration of stock outs
stocked correctly
RDF drugs Program drugs
Improving visibility along the Pharmaceutical supply chain: A case study on EPHCSS 
 
Master Thesis                                                                           Molde University College  25 
The average duration of stock-outs varied widely ranging from 10 to 147 days: with RDF products 
being the highest from 48 to 147 days out of stock while program drugs staying stock-out relatively 
better with an average of 16.5 days.  
It is only one product which is correctly stocked in all hubs, and another one product where 83% 
of the hubs stocked it correctly. For 4 products, none of the hubs are stocked correctly. And for 
the rest of the products, 15 to 50% of the hubs are correctly stocked.  
The findings for the existence-, frequency- and duration of stock-outs and the proper inventory 
management give a scientific indication for the validity of the empirical experience, which became 
a motivation and targeted areas for this study. 
Generally, the results show performance gaps in product availability, which requires an immediate 
intervention. The interesting thing found is that of the relatively better availability and performance 
metrics for program drugs than the RDF ones. Even if the program drugs performance by itself 
requires improvements, but it would be a good opportunity to further find out in advance studies 
why the program drugs system of supply has relatively better qualities than the RDF categories for 
a benchmarking purpose. 
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3.2 Part II-Supply chain visibility  
The visibility study in the system started with selecting a list of pharmaceuticals to study up on. 
Based on a pharmaceutical analysis report named VEN and ABC (a yearly categorizing of 
pharmaceuticals as Vital, Essential and Non-essential and further cost analysis as, A-covering 70% 
of the budget, B-20% of the budget and C-10% of the budget) conducted by seven regional PFSA 
hubs (Bahir Dar, Diredawa, Gondar, Hawassa, Mekelle, Negelle Borena and Nekemte), a total of 
11 products from the RDF product class were selected by the focal company forecasting team 
group as the top vital and highly consumed, and therefore are taken for this study. 
1. Nifedipine 20mg tablet  
2. Insulin zinc suspension 100IU/ml injection  
3. Chloramphenicol Sodium Succinate 1gm injection  
4. Erythromycin (as Stearate) tablet - 250 mg, 500mg  
5. Gauze Surgical 90cmx100 m mesh size 19x15  
6. Surgical gloves sterile latex No. 7.5  
7. T.A.T. 1500IU/ml injection  
8. Cimetidine 200mg/ml, 2ml injection - CSPC Ouyi Phar. 
9. Cotrimoxazol (Sulphamethoxazole + Trimethoprim) Supension 240mg/5ml  
10. Amoxicillin 250mg,500mg tablet 
11. Ciprofloxacin 500mg Tablet  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9; VEN and ABC standing for the selected 11 RDF pharmaceuticals 
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In case of the program pharmaceuticals, as there was no data analysis regularly made, five 
products, which has high number of clients, were selected from each product group(Anti-TB(1), 
Anti-Malarial(1), ARV(2), Family Planning(1)).  
12. Lamivudine 300mg/Tenofovir 300mg/Efavirenz 600mg Tablet,  
13. Zidovudine 300mg/Lamivudine 150mg/Nevirapine 200mg Tablet 
14. RHZE (150mg+75mg+400mg+275mg) 0f 6x28 + RH- (150mg+75mg) of 12x28,Kit 
15. Artemether + lumefanthrine ( 20 +120)mg 6X4,30  
16. Medroxyprogesterone acetate 150mg/ml in 1ml,Vial 
 
Therefore, a total of 16 pharmaceuticals were selected. These 16 products are supplied by 15 
different suppliers; of which, four (4) are locally based while eleven (11) are international.   
 
 
 
 
 
 
 
             
                       Program (Int.)     RDF (Int.)     RDF (Local)  
 
 
 
 
 
 
 
                    
 
Figure 10; Local versus international suppliers supplying strength 
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 Figure 11; In-bound supply chain network, with the list of suppliers 
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 3.2.1 Section-I, Inbound Supply Chain Visibility Measurement  
3.2.1.1 Sub-Section- I // PFSA-RDF Suppliers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In a supply network, global visibility is a combination of the visibility that the focal company has 
of the different nodes of its inbound or outbound supply chain. Therefore, in order to have a global 
measure of supply chain visibility, the focal company’s visibility of each node, i.e. a single supplier 
or a cluster of similar suppliers in terms of size and location is first calculated in this section and 
towards health institutions (the outbound) in section two. 
The data exchange between two nodes regard different types of information, therefore as per the 
methodology, four types of information flows that the manufacturer exchange specific to the 
identified pharmaceutical product is identified out. The information flows gathered from the 
suppliers are quite the same for those members of suppliers within the international and local 
category.  
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Figure 12; In-bound and outbound supply chain, partial visibility index overview 
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Table 4; List of information within local and international suppliers of RDF products 
 Type of Information flows 
Type of 
informati
on flow 
generated  
Transaction/Events Status information Master data Operational plans 
Type of 
supplier  
Local 
 (11) 
International 
(13) 
Local 
(3) 
International
(2) 
Loc
al 
(7) 
International
(7) 
Local 
(3) 
Internation
al 
(3) 
 1.Payment 
registered  
2.Payment 
confirmed 
3.Product 
demand 
captured  
4.Production 
completed 
5.Order 
received  
6.Order 
confirmed  
7.Order 
modified  
8.Order packed 
for shipment  
9.Order 
processed 
10.Product sent  
11.Production 
order sent 
 
1.Payment 
registered  
2.Payment 
confirmed 
3.Product 
demand 
captured  
4.Production 
completed 
5.Product 
warehoused  
6.Bid request 
issue 
7.Client order 
received  
8.Order 
confirmed  
9.Order 
modified  
10.Order 
packed for 
shipment  
11.Order 
processed 
12.Order 
shipped 
13.Production 
order sent 
1.Produc
tion in 
progress 
2.Produc
t ready 
for 
shipmen
t  
3.Produc
t stock 
level 
 
1.Productio
n in 
progress 
2.Product 
stock level 
 
1.Product type  
2.Stock keeping 
unit 
3. Batch number 
4. Manufactured 
date  
5. Expired date  
6. Shelf life 
7. Hub name for 
shipment  
 
1.Production 
quantity and type 
2.Forecasted 
production quantity 
3. Planned 
production type 
planned 
 
 
Measuring the visibility of individual nodes 
Quantity and quality judgements are collected for each type of information flow (i.e. 
transactions/events, status information, master data and operational plans) and for each supply 
chain node.  The quantity and quality visibility is measured using three scales:  
 The quantity of exchanged information (Table 14)  
 The quality in terms of accuracy (Table 15)  
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 The quality in terms of freshness (Table 16).  
The scales have four response levels (Annex 6.6). As far as freshness is concerned, different 
information flows have different requirements in terms of frequency of updating. Therefore, 
transactions/events are judged as “fresh” only if they are updated frequently, while master data are 
considered “fresh” even if the frequency of update is much lower than that for transaction/events. 
For this reason, the description associated to each response level in the freshness scale depends on 
the type of information flow analyzed (Annex 7.0). 
Final vales, to judge and mathematically analyze the visibility of each type of information flow 
and feature (i.e. quantity, accuracy and freshness), are collected. 
                             
Table 5; The collected values for each type of information flow and feature 
 
 
Suppliers 
 Graded value as per the metrics 
(Minimum value=1, Maximum value=4) 
 
Scales  Transaction/Events  Status 
Information  
Master 
Data  
Operational 
Data  
Local  Quantity  4 4 4 4 
Accuracy  3 3 3 4 
Freshness 1 2 1 2 
International Quantity  4 4 4 4 
Accuracy  3 2 3 3 
Freshness 1 1 2 2 
 
Table 5 indicates that, the focal company accesses more than 75 % of the information that are 
exchanged within RDF local and international suppliers. The problem is when it comes to the 
quality of the access. The accuracy of how those information are accessed ranges from 2 to 4 while 
how fresh those information are accessed goes down to 1. To get a partial visibility value per node 
level, further mathematical estimations are done.  
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Mathematical estimation of visibility at each node level 
  
1.  
 
             Node_Visibility_Quantity= √(4𝑥4𝑥4𝑥4)
4
 = 4(local) 
             Node_Visibility_Quantity= √(4𝑥4𝑥4𝑥4)
4
 = 4 (Int.) 
2.  
 
             Node_Visibility_Accuracy = √(3𝑥3𝑥3𝑥4)
4  = 3.22(local) 
              Node_Visibility_Accuracy = √(3𝑥2𝑥3𝑥3)
4  = 2.71(Int.) 
3.  
 
              Node_Visibility_Freshness = √(1𝑥2𝑥1𝑥2)
4  = 1.41 (local) 
             Node_Visibility_Freshness = √(1𝑥1𝑥2𝑥2)
4  = 1.41 (Int.) 
4.  
 
                   
            Node_Visibility_Quality = √(3.22𝑥1.41) = 2.13(local) 
            Node_Visibility_Quality = √(2.71𝑥1.41) = 1.95(Int.) 
5.   
 
              Node_Partial_Visibility of transaction/Events information flow = √(4𝑥3𝑥1)
3
 = 2.28(local) 
             Node_Partial_Visibility of transaction/Events information flow = √(4𝑥3𝑥1)
3
 = 2.28(Int) 
              Node_Partial_Visibility of status information, information flow = √(4𝑥3𝑥2)
3 = 2.88(local) 
             Node_Partial_Visibility of status information, information flow = √(4𝑥2𝑥1)
3 = 2 (Int) 
              Node_Partial_Visibility of Master Data information flow = √(4𝑥3𝑥1)
3  = 2.28(local) 
             Node_Partial_Visibility of Master Data information flow = √(4𝑥3𝑥2)
3  = 2.88 (Int) 
              Node_Partial_Visibility of Operational Data information flow = √(4𝑥4𝑥2)
3  = 3.17(local) 
             Node_Partial_Visibility of Operational Data information flow = √(4𝑥3𝑥2)
3  = 2.88 (Int) 
6.  
 
        Node_overall_visibility = √(4𝑥2.13) = 2.91 (local) 
            Node_overall_visibility = √(4𝑥1.95) = 2.79 (Int)   
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Table 6; Node level partial visibility values summary for local and international suppliers  
Minimum score=1, Maximum score=4 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                Notes; Minimum score=1, Maximum score=4 
Table five summarizes the quantity and quality of information accessing power of the focal 
company towards the two category of suppliers. The quality of information that is accessed is 
middle value below 2 towards international suppliers. The total partial visibility towards local 
suppliers is 2.91 better than international suppliers (2.7).The focal company has better visibility to 
the list of information types identified on table four, towards local suppliers than international 
suppliers under the RDF category.   
 
Node  
(Supplier
) 
Total 
amount  
of visible 
informati
on 
Accuracy 
of the 
overall 
visible 
informati
on 
Freshness 
of the 
overall 
visible 
informati
on 
Quality of 
the 
overall 
visible 
informati
on 
                  Overall visibility of  Node_Ov
erall  
Visibility  
Node_visi
bility  
quantity 
Node_visi
bility 
accuracy 
Node_visi
bility 
freshness 
Node_visi
bility 
quality 
Transact
ion/ 
Events 
informat
ion 
Stat
us 
Info
r. 
Mast
er 
data 
Infor
m. 
Operati
onal  
data  
Informa 
Local  4 3,22 1,41 2,13 2,28 2,88 2,28 3.17 2,91 
Internati
onal 
4 2,71 1,41 1,95 2,28 2 2,88 2,88 2,79 
 
Figure 13; Focal Company’s in-bound node partial visibility 
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Measuring the overall visibility 
An overall measure of the supply chain visibility is obtained by combining the measures of 
visibility of the supply chain nodes. The contribution of each node to the overall measure is 
weighted on the basis of the criterias: Localization, significance and criticality (Annex 7.2). 
For diagnostic purposes, the overall visibility index is broken down by information quantity and 
quality and by type of information flow, so further calculated with other more detailed indicators 
(Annex 7.3).  
 
Over-all supply chain visibility estimation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7 shows procedures followed to reach an inbound overall (RDF) visibility with a final value 
of 2.82.  
 
                 Table 7; The computation of the weight of the node and overall supply chain visibility 
List of suppliers for RDF 
pharmaceuticals based on the 
purchasing power 
Localizatio
n 
  Significance 
wsigk,  
Criticality Node weight based 
on table 11 (Wstd) 
 
(0 or 
√(𝒘𝒍𝒐𝒄.𝒘𝒔𝒊𝒈)) 
Normali
zation 
(Wstd,k) 
Node_ov
erall_vis
ibility 
Supply 
chain_overall
_visibility 
     
A cluster of local suppliers 1 
 
0.56317771 
 
2 0.750452 
 
0.3189 
 
2,91 0.928132 
APF 
Epharm 
Cadilla 
East Africa   
Truskin Glove Pvt.Ltd 
 
1 0.13304302 2 
0.364751 0.1550 
 
2,79 0.432508 
Huanggang Hyangzhou 
 
1 0.08697961 2 
0.294923 0.1253 
2,79 
0.349709 
CSPC Zhongnuo Pharmaceutical 1 0.08539222 2 
0.292219 0.1241 
2,79 
0.346503 
Egyptian International EIPICO 1 0.07219563 2 
0.268692 0.1141 
2,79 
0.318606 
GlaxoSmithKline (GSK) 1 
 
0.04385033 2 
0.209405 0.0889 
2,79 
0.248304 
Vins Biopoducts LTD 1 0.01037521 2 
0.101859 0.0432 
2,79 
0.12078 
CSPC Ouyi Phar 1 0.00498627 2 
0.070614 0.0300 
2,79 
0.083731 
    
2.352914  
  
 Supply_chain_overall_visibility ( ∑ ) 2.8282 
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3.2.1 Section-I, Inbound Supply Chain Visibility Measurement  
 
3.2.1.2 Sub-Section- II // PFSA-Program Suppliers  
The type of information flows, the program pharmaceutical suppliers generate and exchange, is 
quite the same as what is discussed above. This is because those suppliers, which normally supply 
RDF drugs, are also into the business of program drugs manufacturing. In addition to that, the 
standard of procedures and manufacturing practices are common amongst suppliers regardless of 
the product type.  
Therefore, the capacity of the focal company in accessing those information exchanges from these 
suppliers is graded (Annex 7.3) and final values which is used to judge and mathematically analyze 
the visibility of each type of information flow and feature (i.e. quantity, accuracy and freshness) is 
collected. 
Figure 15; The collected values for each type of information flow and feature, program suppliers 
Minimum score=1, Maximum Score=4 
 Transaction/Events  Status 
Information  
Master Data  Operational 
Data  
 
Quantity  4 4 4 4  
Accuracy  3 3 3 3  
Freshness 1 2 2 2  
 
 
Figure 14; Inbound RDF global visibility 
 
 
                                                                                                                
Notes; Minimum score=1, Maximum Score=4 
 
                                                                                                                  
Notes; Minimum score=1, Maximum Score=4 
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Calculating visibility at a node level  
 
1.  
 
         Node_Visibility_Quantity= √(4𝑥4𝑥4𝑥4)
4
 = 4 
 
2.  
           Node_Visibility_Accuracy = √(3𝑥3𝑥3𝑥3)
4  = 3                      
3.  
 
           Node_Visibility_Freshness = √(1𝑥2𝑥2𝑥2)
4  = 1.68  
4.  
 
         Node_Visibility_Quality = √(3𝑥1.68) = 2.24 
5.   
 
           Node_Partial_Visibility of transaction/Events information flow = √(4𝑥3𝑥1)
3
 = 2.28  
          Node_Partial_Visibility of status information, information flow = √(4𝑥3𝑥2)
3 = 2.88 
           Node_Partial_Visibility of Master Data information flow = √(4𝑥3𝑥2)
3  = 2.88 
           Node_Partial_Visibility of Operational Data information flow = √(4𝑥3𝑥2)
3  = 2.88 
6.  
              
          Node_overall_visibility = √(4𝑥2.24) = 2.99  
    
Table 8: Node level partial visibility values summary (Program suppliers) 
 Minimum score=1, Maximum score=4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8 indicates that the focal company accesses more than 75% of the information exchanged 
within program suppliers in a better quality (2.24) than towards RDF suppliers (2.13), even though 
freshness of access is still lower (1.68).  
 
 
 
 
 
 
 
Node  
(Suppli
er) 
Total amount  
of visible 
information 
Accuracy of 
the overall 
visible 
information 
Freshness of 
the overall 
visible 
information 
Quality of 
the overall 
visible 
informatio
n 
                  Overall visibility of  Node 
overall  
visibilit
y  
Node_visibilit
y  
quantity 
Node_visibilit
y 
accuracy 
Node_visibili
ty 
freshness 
Node_visib
ility 
quality 
Transactio
n/ 
Events 
informatio
n 
Statu
s 
Infor. 
Master 
Data 
Inform. 
Operat
ional  
Data  
Infora 
Local  4 3 1.68 2.24 2,28 2.88 2.88 2.88 2,99 
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Unlike the RDF inbound estimations, there is no need of calculating an overall inbound measure 
of the supply chain visibility for program line suppliers as they are already clustered as a group. 
Which means, the already calculated partial visibility can represent the global inbound visibility 
towards program suppliers.  However, the inbound global visibility constituting both the RDF and 
Program suppliers is calculated considering RDF international suppliers, RDF local suppliers and 
Program suppliers’ node partial visibility values and their significance weights. A detailed value 
of the index is then broken down by information quantity, quality and by type of information flow 
for diagnostic purposes, with other more detailed indicators, (Annex 7.4).  
 
 
 
 
 
 
 
 
 
 
 
Figure 16 summarizes the partial visibility values at each node and the final inbound global 
visibility. Partial visibility of the focal company towards RDF international suppliers is the lowest 
with a value of 2.79(4 maximum value), 2.91 towards RDF local suppliers and 2.99 towards 
program suppliers. The geometric average of the global inbound visibility value being 2.94.  
 
Figure 16; Summary of the inbound supply chain visibility 
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3.2.2 Section-II, Outbound supply chain visibility measurement  
3.2.2.1 Sub-Section- I // PFSA-Hospitals (RDF)  
The focal company PFSA, has an extensive line in its outbound supply chain serving more than 
3547 health centers, 311 hospitals and 6,200 health posts (out of the 16,440-where the rest are 
supplied through health centers) across the country. From such a complex network, three hospitals 
are selected based on; 
 Number of patients they serve  
 Level of service (Specialization) 
for studying the outbound visibility of the focal company. 
 
 
 
 
 
 
 
 
 
  
To find out what information are exchanged within the hospitals under the RDF (Purchase) service 
supply chain, the activity diagram of, mainly referred as APTS –Auditable Pharmaceuticals 
Transactions and Services- a system of practice nowadays commonly getting implemented in bigger 
hospitals is mapped,( Annex 7.5 ). 
For the identified information which are exchanged within the hospitals, ‘how well they are 
accessed’ by the focal company is measured from the quantity and quality perspective. Before 
measuring, the information exchanges are categorized into the four categories.  
Twelve kinds of transaction/event, six status, seven master data and two operational kind of 
information are exchanged within the selected hospitals.  
 
Figure 17; Focal companies out-bound supply chain  
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From the master datas, only the information ‘Stocked out product lists by date’ and ‘SKU-stock 
keeping unit’ are accessed, while all the status information and operational plan datas are accessed. 
From the transaction/events, two of the information exchanges are not accessed. The one shaded 
below are information, which are not accessed by the focal company. It is found out that all the 
communications or the means of data access by the focal company is through telephone, e-mails 
and letter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The information that are exchanged within hospitals, as the figure above shows, are very key and 
relevant to affect business processes. Not being able to access those information or being able to 
access them but with poor accuracy and freshness will surely have consequences.  
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The grading of each information type is collected for analysis (Annex 7.6) of the partial outbound 
node visibility.  
Table 9; the collected values for each type of information flow and feature, focal company’s 
accessing potential towards information exchanged within hospitals in the RDF supply line 
Minimum score=1, Maximum score=4 
 Transaction/Events  Status information  Master data  Operational 
data  
Quantity  3 4 2 4 
Accuracy  3 2 2 2 
Freshness 1 1 1 2 
 
Calculating visibility at a node level  
1.  
 
                   Node_Visibility_Quantity= √(3𝑥4𝑥2𝑥4)
4
 = 3.13 
2.  
 
  Node_Visibility_Accuracy = √(3𝑥2𝑥2𝑥2)
4  = 2.21                     
3.  
 
  Node_Visibility_Freshness = √(1𝑥1𝑥1𝑥2)
4  = 1.18  
4.  
 
                  Node_Visibility_Quality = √(2.21𝑥1.18) = 1.61 
5.   
 
                     Node_Partial_Visibility of transaction/Events information flow = √(3𝑥3𝑥1)
3
 = 2.06 
                  Node_Partial_Visibility of status information, information flow = √(4𝑥2𝑥1)
3 = 1.99 
                    Node_Partial_Visibility of Master Data information flow = √(2𝑥2𝑥1)
3  = 1.58 
                    Node_Partial_Visibility of Operational Data information flow = √(4𝑥2𝑥2)
3  = 2.51 
6.  
                 
                  Node_overall_visibility = √(3.13𝑥1.61) = 2.24  
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Even if PFSA is still able to access most of the information that is exchanged within hospitals 
(more than 75 of it), the quality of access is still an issue where those key information are accessed 
late. 
3.2.2 Section-II, Outbound supply chain visibility measurement 
3.2.2.2 Sub-Section- II // PFSA-Hospitals (Program) 
Likewise the RDF supply line, to find out what information are exchanged within the hospitals 
under the Program supply line, the activity diagram of, IPLS –Integrated Pharmaceuticals 
Logistics System- is mapped( Annex 7.7 ) and the kind of information are identified. 
The list of information that are exchanged within the hospitals are listed, categorized and measured 
from the quantity and quality perspective: Seven kinds of transaction/event, seven status, six 
master data and four operational kind of information exchange within the selected hospitals.  
 
The grading of each information type is collected for analysis (Annex 7.8) of the partial outbound 
node visibility.  
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Table 10; the collected values for each type of information flow and feature, focal company’s 
accessing potential towards information exchanged within hospitals in the Program supply line 
Minimum score=1, Maximum score=4 
 Transaction/Events  Status information  Master data  Operational 
data  
Quantity  4 4 4 4 
Accuracy  3 3 2 2 
Freshness 1 3 1 2 
     
Calculating visibility at a node level  
1.  
 
                 Node_Visibility_Quantity= √(4𝑥4𝑥4𝑥4)
4
 = 4 
2.  
 
                  Node_Visibility_Accuracy = √(3𝑥3𝑥2𝑥2)
4  = 2.44                     
3.  
 
                  Node_Visibility_Freshness = √(1𝑥3𝑥1𝑥2)
4  = 1.56  
4.  
 
              Node_Visibility_Quality = √(2.44𝑥1.56) = 1.95 
5.   
 
                 Node_Partial_Visibility of transaction/Events information flow = √(4𝑥3𝑥1)
3
 = 2.28 
              Node_Partial_Visibility of status information, information flow = √(4𝑥3𝑥3)
3 = 3.29 
               Node_Partial_Visibility of Master Data information flow = √(4𝑥2𝑥1)
3  = 1.99 
               Node_Partial_Visibility of Operational Data information flow = √(4𝑥2𝑥2)
3  = 2.51 
6.  
           
                Node_overall_visibility = √(4𝑥1.95) = 2.79  
  
The findings from the above estimation shows PFSA’s better access of information towards 
hospitals in the program supply line (2.79) than the RDF supply line (2.24).At the same time, the 
quality of information access has grown from 1.61(during the RDF supply line)  to 1.95(during 
the program supply line). All the values of visibility so far calculated are collected in figure 19 for 
further discussion regards to the research question. 
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Figure 18; Final outbound and inbound global 
and partial visibility values summary tree 
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Research question 2: 
 How is Supply Chain Visibility implemented in EPHCSS? 
 
The study shows that in the inbound supply chain, the focal company has a better partial visibility 
(2.99/4) with regard to foreign suppliers of program pharmaceuticals than with the local suppliers 
(2.91) and international suppliers (2.79/4) of RDF pharmaceuticals.  
 
Even if more than 75 % of all the information flow within the inbound suppliers is accessed by the 
focal company, but the accuracy of the accessed information is of intermediate score (2.9/4)and 
the freshness is indeed very poor (1.6/4). Operational data are those information flows accessed 
with better accuracy and freshness while transaction/events information flows with least freshness 
score. Accessing in a relatively better accuracy and freshness, the production quantity and 
forecasted type of products by a supplier might be important for the focal company but it is not as 
important as freshly and accurately accessing the status and transaction information when it comes 
to improving their supply chain performance. By accurately and freshly knowing the status of their 
orders, the stock status and the production amount in progress of their suppliers -the focal company 
could make informed decisions to avoid stock-outs .  
 
Comparatively similar result is recorded in the outbound portion where information flows within 
hospitals for the program pharmaceuticals supply line are better accessed(more than 75% 
accessed) but with moderate quality; accuracy (2.44/4) and freshness (1.56/4) than the RDF supply 
line; accessibility (3.13/4),accuracy (2.21/4) and freshness (1.18/4).  
 
In both of the situations, the hubs does not have a better freshness and accuracy visibility index to 
the transaction and status information of health institutions which probably contributes to the poor 
supply chain performance indexes: frequent and high duration of stock-outs at health facilities.  In 
order to avoid the buildup of unused stock, and intervene stock-outs at both facility and hub level 
at its earliest stage, the hubs need to know the real time true consumption and stock level progress 
of facilities: the status and transaction information accurately and freshly. In the finding, the 
overall visibility of transaction and status information is relatively lower in the case of RDF supply 
line (T (2.06/4), ST (1.99/4)) than the Program supply line (T (2.28/4), ST (3.29/4)). Having  a 
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better visibility of facilities product status information contributes to a better decision making and 
better performance which is shown by the correlation of program drugs better visibility, better 
performance and better availability of products than the RDF ones. Accessing accurate and fresh 
status information at facility level would help hubs to quantify and forecast the true demand of 
lower levels and therefore could mitigate the bullwhip effect, (Zhao et al. 2002).  
 
There are key things understood from the findings. Primarily, there is a relatively better visibility 
within the Program supply line. The RDF supply chain shall find out what current practices and 
working procedures has made the program supply line relatively better to benchmark their scores 
to line up by taking diagnostic measures.  Secondly, as discussed above on the sequence, as long 
as the information we want it visible are critical and key for decision making and can have the 
potential to trigger better supply chain performances , both the RDF and program supply lines shall 
strive to find possible ways and shall implement optimization and automation of their processes to 
enhance their supply chain visibility: to boost the freshness and accuracy of their current 
information access pattern which is found to be poor according to the findings of this study.  
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3.3 Part III-Improvement approaches to enhance the visibility  
3.3.1 Section-I: Process model design, improvement point’s identification and approaches 
To identify reasons for insufficient supply chain visibility within the study system and figure out 
points for improvement possibilities, a time series analysis of chronological sequence is done.  
Basing on the insights from the case study, a process model is designed coherent of the individual 
supply chain process steps and actors of the system. Designing the process model helped to identify 
unused potentials for transparency improvements and needs for recommending approaches. 
Therefore on the process model, between different actors within the processes, many points are 
identified which are critical for the creation of the research problems.  Almost all of these processes 
are manually performed as also indicated by percentage of orders placed through electronic 
ordering system analyzed on analysis-I, very few of the processes are already supported by 
appropriate technologies (I would rather say, only data base management systems are so far in 
use), therefore require the support of more economic friendly approaches. 
 In order to provide supply chain visibility, it is obvious and crucial to implement process 
automation. Through automation and technical support, thus, improvement potentials can be 
resulted. 
Before suggesting the derived visibility improvement approaches, points of tension areas-those 
contributing to the creation of the research problems and analysis of improvement points are 
presented based on the process model design. 
The process model is designed into three categories of major processes; to delicately represent the 
supply chain processes of the system.  
1. Quantification for national procurement (Process diagram 1-figure 20) 
Under this division are those process activities from quantification of pharmaceutical products 
until a contracting is signed with a supplier and consequent follow-ups. It shows the overall 
processes involved in procurement of pharmaceuticals by the focal company-PFSA. Everything 
starts from health facilities as they play the primary role in quantifying their total annual needs. It 
is then the duties of the regional PFSA hubs to summarize the reports/annual purchase requests of 
health facilities and forward it to the central hub FCB (forecasting and capacity building) unit as 
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an aggregated annual hub requirement (AAHR). The PD (procurement department) unit of central 
PFSA get into the practices of supplier selection, contracting and procurement.  
2. Procurement Supply and Request refill (Process diagram 2) 
This portion of the diagram originates from the manufacturer, as a continuation of the first portion, 
whereby the central PFSA (Importer) is supplied with the products ordered. Then the next figures 
show the refill/supply of stock to the lower levels until a single pack of medicine is dispensed to 
the end-customer.  
3. Stock refill (Purchase) Request (Process diagram 3) 
Here are only two actors accounted: health facilities and regional PFSA hub. This part dictates the 
IPLS product refill or purchase request by the health facilities to regional PFSA hub. And at the 
same pace, regional PFSA hubs stock refill request to their next higher tier: Central PFSA.  
Points identified out  
For each of the research problems, the tension process areas are identified out.  
3.3.1.1 Poor inventory management [IM]  
 Frequent product stock-outs  
 Inventory overstock  
The process activities labeled with IM, are those supply chain processes which (from the insight 
of the case-study, literature reviews and part-I findings) are found out to be contributing factors 
for the frequent stock-outs and inventory overstock.  
3.3.1.1.1 Under the category of ‘Quantification for national procurement’  
IM1 Annual demand quantification at the health facilities level  
The quantified demand of pharmaceuticals from public health facilities is the basis for the agency’s 
procurement plan. The quantification is theoretically based on factors like; past consumption data, 
morbidity profile, demographic data and yearly budget of the health facility. It is mainly the 
decision of the health professional (pharmacy head) to search for the input data figures and feed 
in the APR (annual purchase request). There are minimal ways the upper tier could prove whether 
the APR coming from facilities is in fact calculated based on consumption data. In the process of 
generating APR based on consumption method, health facilities also consider stock out periods, 
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service expansion or contraction and possibilities of future increase in demand based on specific 
situation in their catchment – which makes the quantification more of an estimation.  
IM2 The collection, analysis, evaluation and aggregation of APR at the regional PFSA 
Gaps in the accuracy of the quantification estimation at the regional PFSA hubs which take into 
effect lower tier requests is also an issue. Demands of non-governmental health facilities (whose 
demand is unreal, swinging and shown creating bullwhip effect within the supply chain) is 
included in to the aggregated annual requirement of the hub, where private importers and 
wholesalers fail to satisfy. 
IM3 Final analysis with VEN and ABC by Central PFSA FCB  
The final quantification coming from the hubs which passed through many uncertainties, the 
‘aggregated annual hub requirement ’, is itself analyzed by the central PFSA FCB against many 
uncontrolled variables: planned health service expansion, past consumption, stock-out periods, 
service statistics and budget reference.  
Therefore, from this category and the above three main tension areas; two contributing factors to 
the mentioned problem are identified out  
 Inaccurate and inadequate data availability for quantification during the yearly 
procurement  
 Budget constraints  
3.3.1.1.2 Under the category of ‘Procurement supply and refill’ 
These constitute supply chain processes for the delivery of the product to the focal company which 
already is ordered and stock refill constitute those processes where the stock is to be processed 
from a stocked inventory to be issued to lower tiers. The following key processes from this 
category are found out to be responsible for the research problem of poor inventory management. 
IM4 Order processing at the pharmaceutical manufacturer 
Even if pharmaceutical suppliers fill rate is good, but other factors like longer lead time and 
emergency production incapacities contribute to stock-outs or overstock inventories at the lower 
level. 
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The stock quantification and analysis part at this sub-class require consumption trend of facilities 
and their genuine stock request data. Inaccurate and inadequate data feed to the processes create 
the research problems later on.   
IM5 Quantification and rationing at central PFSA  
IM6. Analysis and rationing at regional PFSA  
3.3.1.1.3 Under the category of ‘Stock-refill request’  
IM7/8. Stock request processing at health facilities and regional PFSA  
3.3.1.2 Counterfeit products within the legitimate supply chain [CO] 
The process activities labeled with CO, are those supply chain processes which (from the insight 
of the case-study and literature reviews) are possible gateways for counterfeited products into the 
legitimate chain. 
CO1. Selection of suppliers at Central PFSA PD  
Those suppliers who have a contact with sub-standard drug makers may compete for a bid. 
Therefore, selection of suppliers could be one key area for a gateway of counterfeit medicines.   
CO2. Delivery by the pharmaceutical manufacturer 
The key inflows and outflows of counterfeit and sub-standard medicines are in-between this steps 
after the legitimate manufacturer shipped their original products but which are diverted and 
exchanged with the fake ones on the journey.  
CO3/4. Stock receive and delivery to the lower tiers at the central and regional PFSA 
Receive are also common gateways where hubs unknowingly or deliberately receive on route 
exchanged counterfeit medicines which later go down and consumed by the end-user.  
3.3.1.3 Poor traceability of product [Tr] 
The process activities labeled with ‘Tr’, are those supply chain process points through which a 
(from the insight of literature reviews and similar studies) product can be tracked/traced when 
there is a drug-recall.   
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Tr1. The point of exit from the pharmaceutical manufacturer  
This process steps are the first tracking points where the manufacturer is able to register each 
product that is getting out of its unit. Having accurate and real-time data here is a vital requirement.  
Tr2/3/4/5/6/7. GRV recording or HCMIS/Bin /Stock card updates at central, regional PFSA and 
health facilities when a product is received 
Facilities including the importer and regional wholesalers and health facilities manually and 
electronically register (database except health facilities) the product specification they receive and 
issue. But as the data input method is mainly manual, and the actors rely more on paper records, 
tracing of a given product at some instant time is hectic.  
Tr8. Bin-card updates (done every time a product is issued to a patient) at the health facility level 
The story is the same for the health facilities’ too. The big unique thing here is that, the patient 
information who took a specific drug could never be traced as there is no registry made about 
patient information by the time of a drug dispense. At the same time, records for an issue of a drug 
to an end-user is not made. 
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Process model design and Improvement point’s identification  
Figure 19:  Process Diagram 1- Quantification for national procurement 
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Figure 20: Process Diagram 2- Procurement Supply and Request Refill (based on IPLS) 
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Figure 21:  Process Diagram 3- Stock refill ( Purchase) request 
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3.3.2 Section-II; Recommended approaches  
Based on the insight of the case study, reference of similar projects and cases from the 
literature and my advisors personal expertise; the following sub-chapters present two 
improvement approaches for targeting the tension areas and for accessing the potentials. 
Research question 3: 
 What are those approaches through which the supply chain visibility could be improved 
under the constraints of EPHCSS? 
Primarily, GS1 Data matrix barcoding unique identification and database authentication 
system for efficient tracking and tracing of items and shutting off counterfeit and sub-
standard drugs smuggle into the system. Secondly, a real-time inventory dashboard which 
is automatically linked with the scanning system and the already established system database 
management (HCMIS) to mitigate inventory management challenges are the two approaches 
this study recommends.  
3.3.2.1 GS1 Data Matrix Unique identification and database authentication system  
Standard-based pharmaceutical traceability solution enables stakeholders to capture and 
share defined product information between trading partners, increasing the security of the 
extended supply chain. Labeling packets with GS1 will secure the pharmaceutical supply 
chain against counterfeiting by giving actors the capability and confidence in confirming the 
legitimacy of the products they receive, (GS1 July 2015).   
The key components needed to be deployed for this improvement approach are two things: 
GS1 Data matrix labeling;  
GS1 data matrix is a key data carrier chosen as it is emerging across the world as the 
preferred data carrier in health care, due to the fact that it can hold the same amount of data 
as a linear data carrier but takes up less space whilst providing error detection and correction 
capabilities. 
For this system, GS1 matrix is better to be structured to carry four element strings with 
related application identifiers (AIs): Highest level of AIDC (automatic identification and 
data capture) marking.  
 GTIN (Global Trade item Number)  
 AI (01) –Unique identification for the manufactured drug 
 Expiration date AI (17)  
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 Batch Number AI (10)  
 Random Serial Number AI (21) –Randomized, non-sequential event serialization for 
every single pack  
In the production phase, the manufacturer prints a unique GS1 Data matrix code symbols on   
the product packaging. 
Database application Platform Copying/Updating  
The second requirement is to have a database where those unique codes are to be stored 
every time a product is manufactured so that they could then be accessed by lower tier 
actors.GS1 has its own global data synchronization network (push database system). For 
security purposes, having a primary database accessed only by manufacturers and a 
secondary database accessed by many actors within the chain (importer-PFSA main hub, 
wholesaler-regional hubs, and health institution pharmacies) for authentication purposes 
would be safer. 
After the codes are labeled, the 4 data elements (GTIN, expiration date, batch no. and serial 
no) and related information (e.g. active ingredient and/or drug specifications) will be 
uploaded to a primary database application platform accessed by manufacturers.  
The code is then copied on a second database, which is accessed, by the importer, wholesaler 
and health institutions. When product cartons are dispatched from the manufacturer, all 
related information are updated and shared on the platform and can be accessed by the 
importer, wholesaler and pharmacies (health institution).  
The database is modeled on GDSN (Global Data Synchronization) standard, holding the 
master data of each medicine (GTIN).  
The importer, wholesaler and pharmacies can authorize the items they receive by checking 
the codes on the packages through scanning from the GDSN every time they receive orders 
for authentication.  
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Even though the GS1 integrated data matrix coding could ensure the system with unique 
identification and securing of the chain, but from the insights of the case study we also see 
two practical issues which need to be considered here; 
1) To authenticate product packages, every code has to be scanned before receive, which 
would become unideal to do in cases where the actors transact bulk number of items 
each day(considering GS1 data matrix- which require a direct line of contact for 
scanning for each of the tagged product). This bulk product movement is a day to day 
activity, therefore the warehouse professionals may become reluctant in authenticating 
products and may receive the stocks without any scans/authentication. This creates a gap 
and a good opportunity for the counterfeited drugs to surge into the system.  
2) Automatic identification technologies like the RFID codes which doesn’t require a direct 
contact of scanning and able to scan bulk items at ones are very suitable for such a 
problem but that would be difficult to implement it at the item level on the current system 
mainly for two reasons: 
The first is the cost of each electronic tag, which would make most medicines prohibitively 
expensive and place them outside the boundaries of established price ceilings, both 
government and market imposed. Secondly and perhaps the greatest impediment to item-
level tagging by RFID is that the consumer does not carry RFID readers to decode the radio 
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Figure 22: GS1 data matrix with 
GDSN database 
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signal thereby fails to include the consumer in the authentication process. But RFID may 
probably be considered for high-value products by undergoing ROI (return on investment) 
further studies.  
 
Therefore, what we suggest in addition to the GS1 data matrix authentication is an 
implementation of an end-user enabled authentication system platforms.  
Referring to projects in India, Malaysia and the European union,(Gupta, K. Singhal, and 
Pandey. 2012, Afify and Mabrouk 2013 , Sinha 2012),end-user authentication can also be 
possible even with the GS1 data matrix identification where every strip of medicine 
available ought to have a unique randomly generated numeric code – AI (21) and where the 
end-user (clients) can SMS the code and a message referring to the database will tell the 
consumer whether the drug is original or not. 
 
 
 
 
 
 
After a customer confirmed the codes through sms, the unique codes are then decrypted from 
the database as ‘used’. There will be extremely little incentive for the counterfeiters to steal the 
unique codes from legitimate supply chain packages of products because it will be tiresome for 
them to wander and steal the unique codes per the simplest dispense unit. As a second 
implementation strategy, and basing on further studies, the unique codes can be tamper-evident 
(scratch-off labels) which need to be unveiled only during messaging,(mPedigree 2016). 
mpedigree which is already practical in Nigeria, Ghana, Kenya can be a good alternative of 
tamper-evident codes and authentication. 
Authenticating drugs until the tip point of pharmacies may not be enough in cases like Africa 
or Ethiopia because smuggled drugs may deliberately be sold by pharmacies (Health 
institutions) as long as they find it cheap and profitable to sell, (Sahle et al. 2012). Therefore, 
the extra purpose of enabling the public with a friendly and easy to use self-authentication of 
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Figure 23: GS1 data matrix 
code package marking 
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medicine legitimacy is a key implementation portion. Enabling clients(end-user) themselves 
who are always vigilant about fake drugs to check authenticity just within few seconds of user-
friendly service closes the gaps; at least lives could be saved.  
 3.3.2.2 An Integrated Inventory Dashboard linked with the scanning system and the 
already in-use company inventory database management (HCMIS)   
One of the most important motivations behind any integrated supply chain management is to 
eliminate the barriers by enabling the synchronization and sharing of valuable information 
among stakeholders. The success of the whole process depends on the level of the visibility of 
the pharmaceuticals at each hub, suppliers, and health institutions in a common interface for 
responsible professionals. The improved visibility of such information coupled with informed 
decision making would yield significant benefits in inventory management, resource utilization 
and product distribution,(Delen et al. 2011, Wang, G., and Wei 2007).  
The second proposal therefore deals with a dashboard .The data matrix scanning has not to be 
merely for authentication purposes, but also as a gateway to the status update of products on a 
dashboard interface. Immediately when an item is authenticated, the inventory data is 
recorded/updated in the dashboard. The same is true when an item is issued out. So that being 
at a central level (PFSA main hub), decision makers and professionals could real-time look at 
the inventory data of regional hubs and health facilities. The integration of the currently existing 
HCMIS inventory management systems at hubs, with the automatic data input from the data 
matrix scanning would make data entry to an electronic stock control easy and fast. What we 
have figured out from the case study is that, hubs HCMIS is updated late even after receive of 
a stock. Primarily the hubs give high consideration to paper receive documents (GRV- goods 
receiving voucher). The reason we found out is that,  
1) The items hubs receive need to be first sorted out in item name, product amount, batch 
number, expiry date: so that store professionals prefer to sort the items on a former easy to 
use paper receiving formats before they electronically feed the data into the HCMIS-which 
sometimes take even weeks.  
Therefore, we believe creating the link between code identification and HCMIS data input 
avoids the gap here and will change the manual data feeding: By the time a product is scanned, 
it shall appear on the HCMIS screen, and that change is immediately synched to a separate 
web-based interface-inventory dashboard from the HCMIS data base. 
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 From the case study, we found out that the system already has a web-based inventory 
dashboard (which shows inventory data of those eleven hubs which use the HCMIS hub 
edition) which communicates with the HCMIS. But the main problem issues are three; 
1) It is not real-time, it doesn’t show the updated inventory data as the HCMIS itself is 
updated late due to the problems of data-feeding mentioned above. 
2) Health facilities data is not visible on the dashboard, there are few facilities using the 
facility HCMIS based edition. 
3) Organizational: Even for the data already available on the web-based dashboard, 
visually triggered proactive decision making is very poor. E.g figure 27 below shows 
that from a sample of three hubs discussed at part-I, Bahir-dar hub has lots of vital 
product varieties stocked-out at that exact moment where those items are overstocked 
in Jimma and Adama hubs, where organizational measures hasn’t been taken where the 
stock out days stayed from (5, 25 days duration- same until the last date of data 
collection). The ultimate outcome of having visibility boosting solution is to make an 
informed decision making which requires a sustained organizational commitment.  
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Figure 24:  Processes linked; Data matrix scanning, HCMIS data input, Inventory dashboard update  
Figure 25: Inventory dashboard 
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Figure 26: Poor stock distribution among regional hubs showing poor organizational 
proactive inventory decision making 
From one project experience (blood supply chain dashboard development project),(Delen et 
al. 2011), predictive analytics capability could be integrated to the dashboard to yield 
significant benefits in inventory management, resource utilization and product distribution. 
In order to target two of the conflicting inventory management problems of this study: by 
maintaining enough inventories to meet planned demand but at the same time to minimize 
expirations and spoilage, the dashboard can be designed to summarize stock status and 
visually contrast excess and critical inventories being aided by a dynamic report which 
continually analyzes the inventories for products at each facilities based on their 
consumption rates and adopted inventory policy. Therefore from the inventory status 
analyses, it would become more appropriate to make forecasts of inventory and consumption 
in a better accuracy.  
From the insight, it was found that the focal company is often involved in responding to 
emergencies and stock-outs. Mostly deviations of stock (stock-outs, overstock inventory) 
are detected and noticed only when the deviation causes a significant impact on the supply 
chain. To address such rising inventory management problems, we believe that, automated 
means of detecting these problems and bringing them to the attention of responsible focal 
company managers has a greater flexibility in the range  of options to fix the issue. One way 
is by integrating the dashboard stock progress with various alert types (emails, sms) and 
notification mechanisms. Earlier communication of alerts (figure 28) of critical metrics such 
as inventory levels, not-in-stock items, unusual trends in consumption, expiration rates allow 
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supply chain managers to proactively identify problems and therefore develop solutions 
before the problems develop. This would change the reactive working system to proactive. 
 
Figure 27: A sample of main types of alerts from BRAMS project  
The EPHCSS is a complex system with more than 3000 health institutions to serve all over 
the country. Responding to stock-out and overstocks requires visibility into not only the 
current inventory levels at a specific location but also the availability, proximity, and 
accessibility of inventory in all locations.  In order to facilitate such rich visibility, the 
dashboard should also allow the integration of user interfaces like the GIS (Geographic 
based information system) – for a visual illustration of an optimized transportation plan and 
facility level inventory information.  
 
 
 
 
 
 
 
 
Figure 28: Balancing inventory network by supply chain optimization enabled with GIS and 
facility level inventory and transportation information 
 
Source: Own work 
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As an example, the stock status of insulin injection (one of the most vital medications which 
needs to be 100% available) is reviewed with GIS integrated interface (figure 29), the bars 
show the amount of stock in inventory at the sampled PFSA hubs (Current inventory data 
taken from part-I of this study) and the connecting lines proposing efficient ways of 
transportation plan for moving the products around the network to meet the shortages and 
excess inventories at various locations.  
3.3.3 Section III: Supply chain visibility solution scorecard  
Supply chain visibility projects get off-track because they focus on functionality as a benefit 
in itself. This is not an accurate understanding of why visibility adds value. Features of a 
visibility system or process are only valuable to the degree that they fit into the targeted 
business decision, (McIntire 2014).  
 
As an example, if a visibility process delivers beautiful visualizations of the meta-data, such 
as by plotting flows of materials on to a map, this is an interesting feature. But if the targeted 
business decisions don’t have use for the feature, then it’s not going to add value to the 
company. Therefore in this supply chain visibility solution scorecard, the degree to which a 
visibility process meets the targeted business needs of the decision making process and the 
output offered by the visibility process, fitness, is measured.   
 
On the high end is a 100% fitness, where the visibility solution literally fully automates the 
decision at or above levels possible by a human being. At the other end is zero percent 
fitness, where the system adds nothing meaningful to the decision-making process.  
 
In this visibility solution scorecard, first to calculate fitness percent score, a four metric are 
graded with scales (annex 8.0) to assign a score to each metric and each targeted business 
decision, then the scores summed and divided by 24(the total sum value of all grade scales).  
 
Second, the cost metric came in to play so as to compare visibility fitness across two options. 
The fitness percentage for each option is plotted against cost in an efficiency frontier.  
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Visibility Solution Name: GS1 data matrix barcoding + GDSN + Inventory Dashboard  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Estimated Total Cost: __10,000 Euro3____    Overall fit %: ___35.38%____ 
 
 
 
Visibility Solution Name: GS1 RFID with passive tag + EPCIS + Inventory Dashboard  
 
 
               
 
 
 
 
 
   
 
 
 
 
 
                                                 
3 Estimate is taken from : an amount of another case study ( considering direct operating cost and fixed asset 
cost) and a simple rough estimation (annex 10.3 ) 
Targeted Business Decisions which the visibility 
solution should support 
Sensitivity Accessibility Intelligence Decision 
Relevance 
Fit % 
Inventory Management (IM)       
Annual Demand Quantification 1 3 0 1 20.8% 
Analysis/Evaluation/Aggregation of APR  1 3 0 1 20.8% 
Final Analysis (VEN/ABC analysis)  1 3 0 1 20.8% 
Quantification/Rationing  2 3 0 1 25% 
Analysis/Rationing 2 3 0 1 25% 
Stock request process 3 3 4 2 50% 
Counterfeit detection (CO)      
Selection of supplier 0    0% 
Delivery and Receive authorization 4 4 3 5 66.6 % 
Tracing (Tr)  4 4 3 2 54.1 % 
Manufacturer delivery inform. Record      
Actors receive inform. Record       
Actors issue inform. Record       
Table 11: GS1 data matrix solution visibility score-carding fitness score 
 
Targeted Business Decisions which the 
visibility solution should support 
Sensitivity Accessibility Intelligence Decision 
Relevance 
Fit % 
Inventory Management (IM)       
Annual Demand Quantification 1 3 0 1 20.8% 
Analysis/Evaluation/Aggregation of APR  1 3 0 1 20.8% 
Final Analysis (VEN/ABC analysis)  1 3 0 1 20.8% 
Quantification/Rationing  2 3 0 1 25% 
Analysis/Rationing 2 3 0 1 25% 
Stock request process 3 3 4 2 50% 
Counterfeit detection (CO)      
Selection of supplier 0    0% 
Delivery and Receive authorization 4 6 4 5 79.16% 
Tracing (Tr)  4 6 4 2 66.67% 
Manufacturer delivery inform. Record      
Actors receive inform. Record       
Actors issue inform. Record       
Table 12: GS1 RFID solution visibility score-carding fitness score 
 Estimated Total Cost: ___100,000Euro
1____    Overall fit %: ____38.52 %________ 
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Figure 29: The efficiency frontier for the two solutions 
Obviously it is of limited use to compare high and low cost options in terms of cost alone. 
But the efficiency frontier gives us a simple and visual display of trade-offs which occur 
between cost and visibility fitness .The dashed line on figure 30 above shows the efficiency 
frontier. Because only two solutions are compared, the frontier may look a bit tricky to 
compare. With a very high increase in investment, the fitness percentage hasn’t increased as 
much from barcode to RFID.  
 
Therefore it is recommendable to consider the GS1 data matrix from this point of view. 
Other similar implementation case studies mention that the return on investment for RFID 
is still ambiguous and unclear(Poirier and McCollum 2006, Bendavid et al. 2012). But the 
management can still consider to study other solutions within the frontier (ERP, VMI) in 
further researches to comparatively visualize the impact their fitness’s have with regards to 
the initial investment with respect to GS1 and RFID.   
 
We believe that with the current recommended approaches, the health system could go one 
step ahead against the current targeted problems, but it would be costly to do if product 
coding is done only by few of the manufacturers, and those few manufacturers may become 
reluctant to participate. Therefore further actions requires the government’s interference to 
enforce all manufacturers to implement the system countrywide.  
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4.0 Summary, conclusion and recommendation for further research  
 
My work experience combined with my academic studies and personal relationship with 
professors at Molde University College, became my motivation to conduct this research study. 
 
Supply chain challenges like poor inventory management, inefficient tracking and tracing, fake or 
sub-standard medicines are of concern for the health supply chain of Ethiopia posing a major health 
risk. There are so far very few scientific studies conducted which focused specifically on PFSA 
supply chain challenges. The ones that exists are informal and non-recent. 
 
To find out where the challenges outlined focusing on PFSA, analysis one of collected 
performance indicators gives an indication of the supply chain performance within EPHCSS.  
 
The supply chain performance indicators from this study asserts the empirically observed existence 
of the challenges within PFSA. Product availability survey within regional hubs show, vital 
products availability ranges as low as 65% to 84.4%, a figure against a 100% availability in the 
service level agreement by the agency. Of the selected vital products, 75% of the commodities 
experienced stock-out for 1 to 4 times within the past 6 months of time for a duration of 10 to 147 
days. Only 16-50% of the products were stocked correctly where understocking being very likely. 
Implication of the forecast accuracy error of (0.22, 0.25 and 2.59) gives an indication that poor 
forecasting probably is one factor towards inefficient product availability for the sampled products 
within the measuring period. The non-practicability of electronic ordering system from focal 
company to suppliers (considering the non-electronic ordering system increases the lead time) and 
an occasional (monthly) stock status monitoring of focal companies to regional hubs were also 
other issues we considered that might be negatively affecting the supply chain performances.  
 
Supply chain visibility is rated as the most important measure to improving supply chain 
performance both by business leaders and researchers. It improves company performance by 
supporting the decision making processes. Therefore, this became the initiative to look at supply 
chain visibility implementation in particular at EPHCSS.  
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More than 75% of the information flows that are exchanged within suppliers and health institutions 
is accessed by PFSA. However, the outbound and inbound supply chain visibility is poor from the 
quality aspect where freshness is below 2 and accuracy between 2.5 and 3(of the maximum value 
of 4). The implication of the values is that: the focal company is not accessing/visualizing in real-
time key information like stock-status and trend of health institutions inventory data which 
eventually would make decision making inefficient and responses more of reactive.  
 
Lastly, by enabling the focal company with approaches which could improve information sharing 
along the chain, data visibility could be enhanced which could ultimately empower an informed 
decision making process and proactive measures so as to improve the supply chain performance 
of the system and combat the key research challenges identified.  
 
GS1 data matrix barcoding with a unique serialization integrated with an inventory dashboard 
within EPHCSS is one cost efficient approach (with respect to the budget of the ministry of health) 
which enables to easily track and trace products movement and offer data visibility as fresh and 
accurate as possible. Accurate, fresh and data rich inventory dashboard would enable decision 
makers to have a proactive approach therefore would trigger a better stock management. A unique 
serialization of products and an authorization at the time of receive and issue would block most of 
the possible ways of counterfeited and unauthorized medicines inflow to the legitimate supply 
chain.  
 
In conclusion, the study confirmed for the samples studied under the measuring period, that 
product availability within the focal company is not as per the service level agreement signed by 
the agency. Most hubs are not stocked according to the IPLS recommended policy of stocking. 
The responsible management body should therefore take this urgent issue of product availability 
and other results of supply chain indicators to consideration for appropriate measures. The 
outbound and inbound supply chain visibility index is better in the amount of information accessed 
by the focal company but the accuracy and freshness of access is found out to be poor. Therefore, 
diagnostic measures on the quality of data visibility should be taken. Conducting similar further 
studies to find out which practices or why the program supply line experiences have a relatively 
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better visibility values over the RDF supply line is advisable. In addition, to have a more detailed 
insight about the impacts of the recommended visibility approaches: we recommend a pilot study. 
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5.0 Research limitations; 
 
In part-I, identification of the kind of information flow and categorizing them under each of the 
information categories was a bit tricky.  
Not finding any quantitative supply chain visibility studies on similar systems limits 
benchmarking.  
Grading of the target decisions with respect to sensitivity, accessibility, intelligence and decision 
relevance was very ambiguous to decide while score-carding the visibility solutions. 
The supply chain measurement is limited interms of the number of pharmaceuticals included and 
the number of indicators selected.  
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6.0 Annexes   
Annex 6.1 Detail personal observation of challenges at PFSA  
Spots from around the warehouse;  
 Products, which required a cold room storage condition, were most of the time being kept in a 
pseudo cold-room, which was not working most of the seasons (The temperature reading of 
the in-house built cold room was most of the time well above 8oc- due to technical failures or 
power shortages). The only kind of management that was applied by the hub until the in-house 
cold room is fixed was usage of cold boxes all around product packages in an assumption to 
lower the surrounding temperature. However, in reality, the ability of this technique to lower 
the temperature; was not more than a myth. It did not go well above moistening the packages.  
 
 As pharmaceuticals are very sensitive kind of commodities, they have and require their own 
standard of space requirement. The expanding stock demand from lower level institutions 
required carrying of higher amount of stock but with the same storage spaces. Due to the 
shortage of enough space, there were many episodes where pharmaceuticals were kept one 
over the other.  
 
Spots from the angle of Inventory Management;  
 Every year the hub ends up with thousands SKU’s of products and with tens of product 
varieties expired and disposed. (E.g. Worth more than 1 Million USD per year burned in 
expired drugs in 2015 from Jimma Hub) 
 Every year the hub ends up with thousands SKU’s of products and with tens of product 
varieties over stocked. ( E.g. IV fluids hold more than 20% of the warehouse space-in most of 
the year) 
 Throughout the year, there were frequent, long period duration Stock-outs of vital, essential 
and non-essential products within health facilities and the hub itself. (In 2012, cross country 
expiry and stock out of two drugs from anti-TB treatment regimen was recorded for 
approximately 1 month and other repeated cases posing a huge health threat.) 
 There were many episodes where, the number of products physical count in the warehouse and 
the count on the stock card/bin-card/electronic system-HCMIS did not match.  
 There were reports of products with high price value, which were missing from the warehouse.  
Improving visibility along the Pharmaceutical supply chain: A case study on EPHCSS 
 
Master Thesis                                                                           Molde University College  70 
 Untimely segregation of expired / damaged products from the normal ones.  
Spots from the angle of Distribution Management;  
 Re-calling of products (due to quality problem) was very tedious and difficult to locate within 
a short period. As in most cases, similarity of batch number on the invoice/STV and the product 
leaving the warehouse is not a necessity making the issue a big problem.  (E.g. Codeine 
Phosphate preparation with life threatening risk is recalled at the end of 2015 by a local 
manufacturer (APF). The recollection process was very sluggish.)  
 Swinging demand flow from facilities made the quantification and forecasting of stock at hub 
level a difficult job.  
 Reports of Pharmaceuticals being diverted or the legitimate ones being replaced with fake ones 
from the distribution line, PFSA to Facilities. (E.g. Cases of theft report for Co-artem is quite 
common (a drug to treat Malaria-one of the many, but frequent) from the legitimate supply 
chain by professionals and non-professionals along the line.) 
 Missed products or missed facilities from the list of products to have been delivered or facilities 
to have been supplied while on delivery.  
 Miscommunication of supply reporting submissions between health institutions, PFSA and 
Regional Hubs.  
 Frequent facility emergency stock requests disturbing the hubs stock balance and adding an 
extra resupply transportation costs.  
 Shortage of ready-to-go distribution vehicles at the time of the distribution week.  
 Un-proper management of storage conditions of ‘cold room’ products during delivery; there 
were no cold-room equipped vehicles for the hub. Products, which required a cold room 
temperature, were managed by keeping them in a cold-room box, staffed with cold bags. The 
vehicles cross more than 500Kms, reaching extremity facilities, taking them more than three 
days, through sunny and humid atmosphere without even changing the cold bags of the cold 
boxes.  
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Annex 6.2 Supply chain visibility enhancing solutions  
 
Product visibility in the supply chain is achieved and improved by tracking and tracing a product, 
possibly throughout its lifecycle, using a variety of methods and technologies like barcode, RFID, 
communication channels and sensor technologies, (Musa, Gunasekaran, and Yusuf 2014).  
Barcodes 
 
Figure 30: the different kinds of barcodes with their historical dating 
The barcode is an optical and machine-readable technology for representing data relating to the 
object to which it is attached. The barcode was first used commercially in 1966, but the very first 
scanning of the Universal Product Code (UPC) barcode was in June 1974. The very common use 
of barcodes is its application. In point-of-sale (POS) management, providing a detailed, accurate 
and current information on sales, thereby accelerates decisions concerning inventory management. 
The two drawbacks of the barcode are that it is a read-only technology – meaning that once printed, 
the data cannot be changed – and the scanner needs a relatively short direct line of sight to the 
barcode. There are two types of bar-codes: Linear (or 1D) and 2D. Linear barcodes represent data 
by varying the widths and spacing of parallel lines. There are many types of 1D barcodes, some of 
them are; Code 39, Code 93, Code 128, Coda-bar, International Article Number (EAN), UPC-A, 
UPC-E, DataBar-14, Interleaved 2-of-5, HIBC (Health Information Barcode), Quick Response 
barcodes (QR codes), PZN (Germany), IMH (Italy), MSI, GS1 Data-Bar Expanded, GS1 Data-
Matrix), publishing barcodes (ISBN, ISSN, ISMN). 2D barcodes are those which encode 
significantly more data and use rectangles, dots, hexagons and other geometric patterns in two 
dimensions to represent data. Among the most popular 2D barcodes are Data Matrix, PDF417, 
Micro PDF417, and 2D Pharma.  
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RFID  
 
RFID provides an alternative means to product identification. The main elements of an RFID 
system are the interrogator (or reader), the transponder (or the tag), and the middleware that 
collects and filters data from the reader before the data is transmitted to enterprise applications and 
information system. The reader and the tag do not require a direct line of sight for communication 
like the barcodes. Some RFID tags offer additional write memory that could serve as storage for 
application data such as the expiry date or date of manufacture, to facilitate data exchange where 
there is no network coverage. The cost of RFID chips remains very high and actually is prohibitive 
for many uses. There are two types of RFID tags, passive ones which are the simplest and cheapest 
types that doesn’t have an onboard power source therefore wait for a signal from an RFID reader. 
They work by relying on the very high-power energy transmitted by the reader while the active 
tags are equipped with an onboard power source therefore could automatically broadcast their 
signal. 
 
GS1 standardization  
 
GS1 system is a set of standards that through its implementations, facilitates an efficient supply 
chain worldwide due to uniquely identified products, logistic units and locations. These standards 
are intended to be global, neutral, and non-ambiguous. They facilitate product and data flow 
between supply chain partners such as suppliers, manufacturers, wholesalers, logistic providers, 
transporters, hospitals. They help automatic data capture and data management, increase data flow, 
reduce cost and secure the supply chain.  There are three key components offered by GS1: 
Identification of a product with unique and global codes of different information and purpose, 
capturing of data from products tagged with barcodes or RFID and sharing of the 
master/transactional/event data captured along the network or common framework.(GS1 July 
2015)  
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There are different policies followed for product marking in GS1. HRI (human readable 
interpretation) information printed adjacent to a barcode or RFID tag represents data carried in the 
barcode or tag (figure 11). When marking healthcare products, GS1 identification keys are used to 
identify trade items and logistic units. Additional data may be associated with the GS1 
identification keys through the use of GS1 application identifiers (AI’s). The following four are 
the common data included while using the 2D data matrix which is the commonly used type of 
GS1 barcode for tagging health care products;  
  
Source:(GS1 July 2015)  
Figure 32: HRI text with GS1 Data matrix label 
GTIN, AI (01)-This is a key for a unique product identification used to identify trade items.  
Batch/Lot-AI (10)-When additional data is required to identify batch number, this identifier is 
used and typically is assigned at the point of manufacture. This additional data is alphanumeric 
with a variable length of up to 20 characters.  
 
Figure 31: The GS1 system of records 
 
Improving visibility along the Pharmaceutical supply chain: A case study on EPHCSS 
 
Master Thesis                                                                           Molde University College  74 
Expiration Date –AI (17)-When additional data is required to identify expiration date, this 
identifier is used.  
Serial Number-AI (21) –If health care products are to be individually tracked and traced using a 
serial number, this application identifier is used. This additional data is alphanumeric with a 
variable length of up to 20 characters.  
When adopting the GS1 standards for healthcare, product marking consideration is given to 
marking levels, product configuration, package hierarchy and distribution channel. The marking 
hierarchy range from direct part mark, primary package, secondary packaging, case/shipper and 
pallet (figure 12). The marking levels range from minimum level providing a GTIN with no 
attribute information, enhanced level providing GTIN plus batch number and expiration date for 
products that require a higher level of traceability control and highest level providing GTIN with 
serial number and expiration date for products that require the highest level of traceability control. 
Figure 33: Package marking hierarchy illustration 
 Source:(GS1 July 2015)  
ERP 
Of the different systems available that allow internal organizational information visibility is the 
ERP system, a software architecture which identifies and plans the resources needed to take, make, 
ship and account for customer orders facilitating the flow of information among the different 
functions within an enterprise. At the core of this enterprise software is a central database, which 
draws data from and feeds data into modular applications that operate on a common computing 
platform, thus standardizing business processes and data definitions into a unified environment. 
By this way, the system provides consistency and visibility or transparency across the entire 
enterprise. A primary benefit of ERP is easier access to reliable, integrated information. A related 
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benefit is the elimination of redundant data and the rationalization of processes, which result in 
substantial cost savings.  
mPedigree 
Being developed by a Ghanaian engineer, Mpedigree is another platform which enabled 
information sharing and visibility for the actors within a supply chain. Established mainly to help 
people affected with counterfeit medicines, (mPedigree 2016) Mpedigree applies the use of mobile 
and web technologies in securing products against faking, counterfeiting and diversion. The 
technology platform made it practical where scratchable codes are printed on medicine packets 
which later are scratched and sent to a number by the patient or health professional as an 
authorization before making the medicine for use.  
QR/CRP/VMI 
Quick Response (QR) was born in the beginning of the 80s in order to reduce delay needed to 
serve the customer in the textile industry. The supplier receives a point of sale data from the 
customer and uses this information to synchronize its production. In the beginning of the 90s the 
Continuous Replenishment Policy (CRP) was developed: based on consumer demand, the CRP 
pull system replaces the historical push systems. Gradually, the sphere of decision of the suppliers 
is growing until the VMI transfers the totality of the customer’s inventory replenishment 
responsibility to the supplier, (Yao, Yuliang, and Dresner 2008, Marqués et al. 2010. ) 
 
Annex 6.3 Information systems in EPHCSS  
 
HMIS (The Health Management Information System) 
The Ethiopian Health Management Information System (HMIS) has been implemented since 2008 
to capture and provide core monitor-able indicators used to improve the provision of health 
services, and ultimately, to improve health status of the population. Since then, the health sector 
has been showing achievements in planning, budgeting, decentralization, review of plans and 
progress, involvement of partners and utilizing information in decision-making. HMIS is a major 
source of information for monitoring and adjusting policy implementation and resource use. At 
the end of 2013, 122 (98%) public hospitals and 2697 (87%) health centers implemented HMIS.  
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HCMIS (Health Commodities Management Information System) (PROJECT 2010) 
 
HCMIS is a warehouse and facility management system developed by the USAID | PROJECT 
(Deliver and SCMS)  for use in the Ethiopian Ministry of Health and the Pharmaceutical Fund & 
Supply Agency (PFSA) to support the country’s pharmaceutical logistics management system. 
The development was initially written for hospitals and high traffic health centers, when it was 
first started in 2008. In 2010, the features were extended to include a warehouse module to support 
PFSA’s hub warehouses. Though both the facility and hub application are developed and 
maintained jointly, they separately referred as HCMIS Facility Edition (HCMIS FE) and HCMIS 
Hub Edition (HCMIS HE). The HCMIS Hub Edition often referred to as only HCMIS is a record-
keeping system to manage daily transactions. Moreover, provides a mechanism by which essential 
and standard working procedures can be enforced in these pharmaceutical settings. Some of the 
standards supported by the system are First to Expire, First-Out (FEFO), batch, and expiry 
tracking. HCMIS is designed to help managers at warehouses and/or facilities to generate 
appropriate and timely stock reports that help them make sound decisions. 
 
Annex 6.4 Roles and responsibilities of actors in EPHCSS  
Table 13: Roles and Responsibilities of PFSA 
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Annex 6.5 IPLS (Integrated Pharmaceutical Logistic System)  
 
IPLS is the term applied to the single pharmaceuticals reporting and distribution system based on 
the overall mandate and scope of PFSA. It was first implemented in 2010 to integrate the supply 
management of Program pharmaceuticals and later RDF ones- aiming to ensure that patients 
always get pharmaceuticals they need and those included on the national pharmaceuticals 
procurement list (NPPL). The long-term plan is direct delivery of all pharmaceuticals in an 
integrated manner to all public health facilities every two months based on demand. 
 
At each level, the system provides accurate and timely data for decision-making where product 
related information flows up from health facilities to the agency whereas products flow from the 
Agency down to health facilities every two months (figure 7). Routine monitoring reports show 
that IPLS is improving information recording and reporting, storage and distribution systems, as 
well as the availability of essential commodities at service delivery points (SDPs).  
 
The mechanisms of reporting and supply pattern are different in each of the categories though; 
Program and RDF.  
 
Program pharmaceuticals reporting and supply  
The reporting for order of Program pharmaceuticals is every two months by hospitals and health 
centers and the delivery/supply by PFSA to these facilities could be directly or indirectly.  
 
Direct delivery sites are facilities that receive program pharmaceuticals directly from PFSA hubs 
whereas non-direct delivery sites are health centers that receive products from PFSA hubs through 
Woreda Health Offices (WoHOs). Health centers and hospitals under direct delivery complete a 
report and requisition format and send it to PFSA Hubs for requisition processing. Whereas, 
WoHO’s complete a report and requisition format for non-direct delivery facilities and send it to 
PFSA branches. The collection and reporting of a Logistics information is every other month by 
health centers and hospitals on logistics management information system (LMIS) forms.  
A copy of the health centre report and order and a copy of each health post report are sent to the 
Woreda Health Office for management and supervision purposes. A copy of the hospital report 
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and order is sent to the Regional Health Bureau for management and supervision purposes. 
The overall information system includes a mechanism for providing ―feedback to lower level 
facilities from upper level facilities. In the feedback reports, facilities will be able to see how they 
are performing compared to other facilities in their area and will be able to facilitate stock transfer. 
 
Figure below illustrates the overall flow of program pharmaceuticals and information in the IPLS. 
RDF pharmaceuticals requisition and supply  
Health centers and hospitals complete RRF (Report and Requisition Format) as per the facilities 
review period, which can be every two-month, every quarter or every six months and purchases 
products from affiliated PFSA branch.  
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Figure 34: Overview of pharmaceuticals and information flow in IPLS 
Source; Own work  
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Annex 6.6 Supply chain performance indicators description  
 
Methodology one  
The methodology is organized by supply chain/logistics functions categorized in four: Product 
Selection/Forecasting/Procurement, Sourcing, Warehousing/Storage, Inventory 
Management/Logistics Management Information/System/Customer Response and 
Distribution/Transport. Each one of these supply chain/logistics functions is then further divided 
by four type of indicators: quality, time, financial, and productivity which are adapted and 
integrated- which is the core point behind this metrics giving it a holistic approach of measurement 
Quality: These indicators are often the simplest to implement and measure. Typically, they tell 
how well the company is performing a specific activity—a common logistics indicator in this 
classification is accuracy— including forecast accuracy error, inventory accuracy, picking 
accuracy, etc. 
Time: These indicators focus on the time it takes to complete specific activities. They show 
whether saving time during specific activities can improve the overall supply chain performance. 
Financial: These indicators identify the supply chain cost drivers . 
Productivity: These indicators examine how well resources are used. For example, filling vehicles 
to their capacity, instead of sending out vehicles half-full, could reduce costs and improve 
efficiency.  
Methodology two  
 
The visibility measure has been developed on the basis of the following basic principles: 
(1) Methodological accuracy. The rigorousity of the output from a scientific point of view. 
(2) Usability. The ease of the model application to real companies 
 (3) Diagnostic support. The model also provided the insight of knowing and helping the user 
identify where visibility should be improved and how this can be achieved. 
The model has components which guided this study throughout;  
1. The main types of information which can be exchanged across the supply chain were classified 
based on the following assumptions and under the following classes.  
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 Transactions/events: Information that has to be communicated when an event takes place 
(e.g. order confirmation, order modification, advanced shipping notice, payment notice and 
sales reporting). 
 Status information: Information that describes the status of some resources or of a process 
(e.g. order status, stock level, sent orders, stocking capacity, residual shelf-life, work-in-
progress, backlog, machine saturation and production residual capacity). 
 Master data: Information linked to the features of products (e.g. basic technical features, 
extended technical features, commercial information, residual product life-cycle, bill of 
materials, managerial product information and stock keeping unit features). 
 Operational plans: Information about the company’s future plans (e.g. distribution plan, 
production plan, strategic sales forecast, operational sales forecast and promotions plan). 
2.  A set of metrics and a measurement model were applied and used to assess the level of supply 
chain visibility quantitatively, globally, partially from the angle of defining the most important 
features of information flows to be considered in the analysis (e.g. quantity, accuracy, speed 
or freshness);both from the quantity and quality aspect. 
 
Instrumental steps and ranking tables for methodology two ( Source: (Caridi et al. 2010a) 
   
 
 
 
 
 
 
 
 
 
Table 14: The scale to judge the quantity of the exchanged information 
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Table 16: The scale to judge the freshness of the exchanged information 
 
 
 
 
 
 
 
 
 
Partial visibility with respect to the nodes (suppliers and hospitals), and with respect to the 
information types is then calculated mathematically by applying the formulas.  
  Node_Visibility_Quantity/Accuracy/Freshness of the focal company =  
√
  
  
  
  
  
  
 (𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦/𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦/𝐹𝑟𝑒𝑠ℎ𝑛𝑒𝑠𝑠 𝑎𝑐𝑐𝑒𝑠𝑠𝑒𝑑 𝑜𝑓 𝑠𝑡𝑎𝑡𝑢𝑠 𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 
    𝑥 𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦/𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦/𝐹𝑟𝑒𝑠ℎ𝑛𝑒𝑠𝑠 𝑎𝑐𝑐𝑒𝑠𝑠𝑒𝑑 𝑜𝑓
𝑇𝑟𝑎𝑛𝑠𝑎𝑐𝑡𝑖𝑜𝑛
𝑒𝑣𝑒𝑛𝑡𝑠
𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 
  𝑥 𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦/𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦/𝐹𝑟𝑒𝑠ℎ𝑛𝑒𝑠𝑠 𝑎𝑐𝑐𝑒𝑠𝑠𝑒𝑑 𝑜𝑓 𝑀𝑎𝑠𝑡𝑒𝑟 𝐷𝑎𝑡𝑎 
𝑥 𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦/𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦/𝐹𝑟𝑒𝑠ℎ𝑛𝑒𝑠𝑠 𝑎𝑐𝑐𝑒𝑠𝑠𝑒𝑑 𝑜𝑓 𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑑𝑎𝑡𝑎 
)
4
 
  Overall_Visibility_of_Status /transaction/master/operational information of the focal company=  
    √
(𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦 𝑎𝑐𝑐𝑒𝑠𝑠𝑒𝑑 𝑜𝑓 𝑆𝑡𝑎𝑡𝑢𝑠/𝑡𝑟𝑎𝑛𝑠𝑎𝑐𝑡𝑖𝑜𝑛/𝑚𝑎𝑠𝑡𝑒𝑟/𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑎𝑙  𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 
𝑥 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 𝑜𝑓 𝑠𝑡𝑎𝑡𝑢𝑠/𝑡𝑟𝑎𝑛𝑠𝑎𝑐𝑡𝑖𝑜𝑛/𝑚𝑎𝑠𝑡𝑒𝑟/𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛   
𝑥 𝐹𝑟𝑒𝑠ℎ𝑛𝑒𝑠𝑠 𝑜𝑓 𝑠𝑡𝑎𝑡𝑢𝑠/𝑡𝑟𝑎𝑛𝑠𝑎𝑐𝑡𝑖𝑜𝑛/𝑚𝑎𝑠𝑡𝑒𝑟/𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 )
3
 
Table 15: The scale to judge the accuracy of the exchanged information 
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An overall measure of the supply chain visibility is obtained by combining the measures of 
visibility of the supply chain nodes. The contribution of each node to the overall measure is 
weighted on the basis of criterias/parameters: 
Parameter 1; Localization in the supply chain(neighborhood), i.e. the distance of each node 
from the supply chain leader both in terms of the number of tiers between the node and the focal 
company and in terms of its vertical integration; 
The main idea is that visibility of “near” nodes (e.g. first-tier suppliers) is much more critical to 
the focal company than visibility of “distant” nodes (e.g. second or third tier suppliers), because 
their operations are much more tightly connected to those of the focal company. The nearer the 
node is to the focal company, the higher is its relevance (i.e. its weight). 
                The localization weight wlock, assigned to a generic node, k, is calculated as; 
 
 
 
 
 
Parameter 2: Significance in terms of value of the goods supplied:  
The more the focal company buys from a supplier, the more interested the focal company should 
be in having visibility of this supplier. So, a higher weight assigned to suppliers who provide 
significant amounts of the overall purchases. 
For the first-tier nodes, the significance weight, wsigk, is calculated as follows: 
 
, where n belongs to the set of first tier-nodes, Z1. 
Parameter 3: Criticality measured using a qualitative scale based on the Kraljic matrix.  
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A four response scale drafted from Kraljix matrix is used to measure the criticality of a supply 
chain node. The scale combined two characteristics:  
 The impact on profits and 
 The supply risk. 
 
 
 
 
 
 
 
 
Assigning a weight to the nodes:  
The weight of a generic node, k, in the inbound supply chain of the focal company is calculated 
based on the assumption that nodes are not included in the analysis if; 
o They are “distant” from the focal company (low wloc), 
o The amount of exchanged goods is not significant (low wsig),  
o They are not critical in terms of supply risk, according to Kraljic (low criticality).  
The threshold W * used to consider the trade-off between the accuracy of the visibility measure 
and the cost of the measure, which both grow with the number of nodes considered into the model. 
The weights of the nodes are then normalized (Wstd, k) so that their sum is one. 
 
 
 
 
 
      
Table 17: Qualitative judgments on the exchanged information criticality 
 
Table 18: The computation of the weight of the node 
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A global measure of visibility: A global measure of the supply chain visibility is then obtained as 
a weighted average of the judgements of visibility of each node. Where N is the number of nodes 
of the inbound supply chain. 
 
 
Methodology three 
The approach bases on the fact that, visibility solution must be interruptive, resulting in a 
different— and better— business decision. Otherwise, with no value created by visibility. It also 
justifies in a way, the only two ways a decision can be improved by supply chain visibility solution: 
if only the solution is able to  
  Improve the information available to the decision mechanism (faster, more accurate, 
more complete, and so on) 
 Improve the decision making mechanics itself (change the individual or group who 
makes it, change the criteria, change the frequency, enforce consistency, and so on)  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: How a visibility solution could improve a target decision 
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These metrics are diagnostic tools for assessing the health of the visibility sub-processes.  
The key enablers/process steps  of 
SCV 
The score-card metrics which was 
used by the approach 
 
       
 
 
 
 
 
 
 
               Figure 36: Supply chain visibility scorecard metrics association with key enablers 
 
Annex 6.7 Supply chain performance indicators analysis  
.  
Stock-out rates  
This indicator measured the percentage of facilities (in this case are the eleven PFSA hubs) that 
experienced a stock out of the three selected products that the site is expected to provide, at any 
point, within 2015 (for one year). The hubs are the main part of the focal company, which are 
responsible to warehouse products and conduct delivery to health facilities.  
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Table 19; Stock-out rates 
Product 
Group  
Product name  Number of hubs that 
experienced a stock-
out of a specific 
product during a 
defined period of 
time (within 2015) 
 
Total number of 
hubs that are 
expected to offer 
that product.  
 
Percentage of 
stock-out 
rates  
RDF/INT CAF inj4  4 
 
11 Hubs 36.3%  
RDF/LOC Amox 5005 
 
0 11 Hubs 0% 
PROG/INT 3TC/TDF/EFV-
adult6  
 
3 
 
11 Hubs 27.2%  
 
Plan in place for predictable change in demand 
This indicator assessed whether the focal company has a plan or procedures in place to adjust stock 
levels to respond to seasonal variance in demand and/or certain campaigns that require surges in 
stock levels. 
 
 
From the focal company’s perspective, a ‘Monthly stock status monitoring’ is done. This report 
tracks quantity at all hubs, at central warehouses and on pipeline. Hub forecasting and capacity 
building officers send reports constituting hubs list of products stock status to the main office 
through email. The report is compiled after a reconciliation of values from the HCMIS (Health 
commodities management information system) database and a manually filled paper bin-card.  
 
 
 
                                                 
4 Chloramphenicol Sodium Succinate 1gm injection of 50 vials 
5 Amoxicillin 500mg capsule 
6 Lamivudine 300mg/Tenofovir 300mg/Efavirenz 600mg of 30 
Is there a formal plan or are there procedures in place to respond to seasonal variance in 
demand and/or certain campaigns that require adjustments in stock levels? (Yes/no) 
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Plan in 
place  
Hubs (Warehouses) 
AA Jim
ma 
Hawa
ssa 
Bahird
ar 
Mekel
le 
Gon
der 
Dess
ie 
Dire
dawa 
Neke
mte 
Adam
a 
Arba
minch 
Does 
the hub 
conduc
t 
monthl
y stock 
status 
monito
ring  
yes yes yes yes yes yes yes yes yes yes yes 
 
Order lead time 
This indicator measured the average amount of time it takes from when an order is placed from 
the focal company to a higher-level supplier to when the ordering facility (the focal company-
PFSA) receives its shipment during a specified period of time. This indicator is usually recorded 
in days but can be calculated over any period of time. 
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Table 20; Order Lead time 
Product 
Group  
Product name  Dates when orders 
were placed  
(is Date when 
purchase order is 
given to the 
supplier) 
Dates when orders 
were received  
(Date when first 
shipment is received) 
Average 
Order 
Lead-
Time 
RDF/INT CAF inj  3 separate orders 
placed on the day 
19/10/2015 
None reached yet, 
 Order 1 : shipped 
on March 9,2016 
may arrive after 
May 9,2016 (is by 
sea) 
 Order 2: will be 
shipped soon (Not 
shipped yet) 
 Order 3: will be 
shipped after 
order 2 
None 
reached 
yet, 
 
RDF/LOC Amox 500 27/7/15  
 
1/9/2015 
 
1 month 
PROG/INT 3TC/TDF/EFV-
adult7  
 
30/10/20148 
 
22/01/2015 
 
1 month  
 
Percentage of orders placed through electronic ordering system 
 
Electronic ordering system here refers to an IT-system used, while conducting a purchase or an 
order, for direct communication with the supplier’s IT-system with no humans involved. 
This indicator measured, orders placed through an electronic ordering system in the first 6 months 
of 2015. 
 
 
 
                                                 
7 Lamivudine 300mg/Tenofovir 300mg/Efavirenz 600mg of 30 
8 Data grabbed only for one of the orders  
Part -I 
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Table 21; Percentage of orders placed through electronic ordering system 
Product 
Group  
Product name  Total number 
of orders 
placed in the 
first 6 months 
of 2015 
 
Number of orders placed 
through an electronic 
system  
Percentage 
of orders 
placed 
through an 
electronic 
system  
RDF/INT 
 
CAF inj 1 None 
Letter from forecasting to 
procurement directorate 
None 
Orders from hospitals to 
PFSA are by using report 
and requisition formats 
i.e. both ordering are 
manual 
0%  
 
Orders made 
through  
-Letter  
-RRF9  
RDF/LOC 
 
Amox 500 1 
PROG 3TC/TDF/EFV-
adult 
 
2 
 
Supplier Fill rate 
A supplier’s ability to fill orders completely in terms of quantity during a definite period of time 
is calculated. Those cases where agreements are made between supplier and recipient to divide an 
order into multiple shipments but still be received, in full, by a specified date, or that substitutes 
can be made were also considered. 
 
 
 
 
 
 
 
 
 
                                                 
9 RRF-Report and Requisition Format  
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Table 22; Supplier fill rate 
Product 
Group  
Product name  Total 
quantity 
ordered in 
original 
PO  
 
Number of 
order SKU 
shipped in 
initial 
shipment  
 
Supplier fill 
rate  
 
RDF/INT CAF inj 50,000 
 
50,000 
 
100%  
RDF/LOC Amox 500 378,802 
 
9,012 (Is 
directly 
shipped from 
local 
manufacturers 
to PFSA hubs 
within the first 
three months) 
 
100%  
10The Local 
suppliers has 
an agreement 
with the focal 
company to 
deliver the 
total amount 
ordered being 
broken down 
in units and 
each quarters 
of the year.  
9,012 is what 
is delivered 
for one 
quarter. But 
they have met 
the total order 
amount at the 
end of the 
year.   
 
PROG/INT 3TC/TDF/EFV-
adult 
 
994,159 
 
 994,159  
 
100%  
Forecast accuracy error 
For all products that the program has committed to supplying, this indicator measures the 
difference between forecasts previously made for a year and the actual consumption or issues data 
for that year. The calculation is based on the mean absolute percentage error (MAPE), usually 
expressing accuracy as a percentage, and is defined by the formula: 
  
                                                 
10 Special Condition  
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where At is the actual value and Ft is the forecast value and n is the number of 
forecasting point in time.  
 
The difference between At and Ft is divided by the Actual value At . The absolute value of the 
result gives the mean absolute error.  
The indicator is calculated for each product for which a forecast is made. 
The data used for forecast is adjusted for this calculation because of the following reason. One, 
focal company’s actual consumption means that of the quantity where hubs have issued to health 
facilities during a year. Hubs report this quantity of issue data every six months. Therefore, the 
data available for actual consumption of a product is of 6 months. Therefore, in order to align the 
forecast which normally is made for a year, it is divided into two and adjusted to give forecast of 
a half year (for the purpose of calculating forecast error). 
Table 23; Forecast accuracy error for the year 2015 
Product 
Group  
Product name  Adjusted Forecast for 
half-year11  
 
Actual consumption or 
issues data (is for 
6months of 2015) 
 
Forecast 
12Accuracy  
RDF/INT CAF inj 42,733 11,879  
 
2.59 
RDF/LOC Amox 500 208,971 
 
166,999  
 
0.25 
PROG 3TC/TDF/EFV-
adult 
 
1,355,392 
 
1,104,546  0.22 
Percentage of Purchase Orders/Contracts Issued As Emergency Orders 
The percentage of purchase orders that are issued as emergency, with a lead time of one month or 
less, out of all purchase orders or contracts placed during 2015 is measured.  
 
 
 
                                                 
11 (Full Year Forecast for 2015 –CAF Inj- 85,466 , Amox 500 -417,943, FDC-2,710,785  ) 
 
12 0 is the ideal value, and as the forecast becomes poor, the value appear far away from 0.  
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Table 24; Percentage of emergency orders 
Product 
Group 
Product name Total number of 
orders placed 
(within 2015) 
 
Number of 
emergency order 
requests (within 
2015)-those orders 
with a lead time of 
one month or less 
Percentage of 
emergency 
orders 
RDF/INT CAF inj 3 POs 
 
0 
 
0 
RDF/LOC Amox 500 2 POs  
 
0 
 
0 
PROG 3TC/TDF/EFV-adult 
 
5 POs 
 
1 
 
20% 
 
Annex 6.8  
Table 25; Availability of vital pharmaceuticals on season of data collection by hub type, April 2016 
Products  Hubs Stock 
A 
Total  
Nifedipine 20mg tablet  6 6 100.0 
Insulin zinc suspension 100IU/ml injection  6 4 66.7 
Chloramphenicol Sodium Succinate 1gm injection  6 5 83.3 
Erythromycin (as Stearate) tablet - 250 mg, 500mg  6 6 100.0 
Gauze Surgical 90cmx100 m mesh size 19x15  6 6 100.0 
Surgical gloves sterile latex No. 7.5  6 1 16.7 
T.A.T. 1500IU/ml injection  6 4 66.7 
Cimetidine 200mg/ml, 2ml injection 6 5 83.3 
Cotrimoxazol Suspension 240mg/5ml  6 5 83.3 
Amoxicillin 250mg,500mg tablet 6 6 100.0 
Ciprofloxacin 500mg Tablet  6 4 66.7 
Lamivudine 300mg/Tenofovir 300mg/Efavirenz 600mg Tablet 6 6 100.0 
Zidovudine 300mg/Lamivudine 150mg/Nevirapine 200mg Tablet 6 6 100.0 
RHZE (150mg+75mg+400mg+275mg) , RH- (150mg+75mg)  6 6 100.0 
Artemether + lumefanthrine ( 20 +120)mg 6 6 100.0 
Medroxyprogesterone acetate 150mg/ml injection  6 5 83.3 
 84.4 
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Annex 6.9  
Table 26; Availability of vital pharmaceuticals in six months prior to survey by hub type, April 2016 
Products Hubs Stock A Total 
Nifedipine 20mg tablet  6 5 83.33 
Insulin zinc suspension 100IU/ml injection  6 3 50.00 
Chloramphenicol Sodium Succinate 1gm injection  6 5 83.33 
Erythromycin (as Stearate) tablet - 250 mg, 500mg  6 4 66.67 
Gauze Surgical 90cmx100 m mesh size 19x15  6 1 16.67 
Surgical gloves sterile latex No. 7.5  6 2 33.33 
T.A.T. 1500IU/ml injection  6 1 16.67 
Cimetidine 200mg/ml, 2ml injection 6 1 16.67 
Cotrimoxazol Suspension 240mg/5ml  6 5 83.33 
Amoxicillin 250mg,500mg tablet 6 6 100.00 
Ciprofloxacin 500mg Tablet  6 4 66.67 
Lamivudine 300mg/Tenofovir 300mg/Efavirenz 600mg 
Tablet 
6 6 
100.00 
Zidovudine 300mg/Lamivudine 150mg/Nevirapine 200mg 
Tablet 
6 6 
100.00 
RHZE (150mg+75mg+400mg+275mg) , RH- (150mg+75mg)  6 4 66.67 
Artemether + lumefanthrine ( 20 +120)mg 6 6 100.00 
Medroxyprogesterone acetate 150mg/ml injection  6 5 83.33 
  66.67% 
Annex 7.0 
Table 27: The quantity, accuracy and freshness of the exchanged information, focal company 
with local manufacturers 
Semi-
quantitative 
judgments 
Transaction/Events Status Information Master Data  Operational Data  
The quantity of 
information 
local suppliers 
generates 
 11 3 7 3 
How many of 
those generated 
information 
does the focal 
company access  
10 3 7 3 
How many in 
percentage does 
the focal 
company access 
91.6% 100% 100% 100% 
The scale to 
judge the 
quantity of the 
exchanged 
information 
4 
The focal company 
has access to a large 
part of the 
4 
The focal company 
has access to a large 
part of the 
4 
The focal company 
has access to a large 
part of the 
4 
The focal company 
has access to a 
large part of the 
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based on table 
14 metrics 
information within 
this category 
information within 
this category 
information within 
this category 
information within 
this category 
How the focal 
company rated 
accuracy of the 
information 
they already 
access 
Scale of 4 , 6 of them 
Scale of 3 , 2 of them 
Scale of 2 , 2 of them 
 
Scale of 2, 1 of them 
Scale of 3, 2 of them 
 
Scale of 3, 4 of them  
Scale of 4, 3 of them  
Scale of 4, 1 of 
them  
The scale to 
judge accuracy 
of the 
exchanged 
information 
based on table 
15 metrics 
3 
The accuracy of the 
exchanged 
information is usually 
satisfactory but the 
information is 
incorrect only in a few 
situations 
3 
The accuracy of the 
exchanged 
information is usually 
satisfactory but the 
information is 
incorrect only in a few 
situations 
3 
The accuracy of the 
exchanged 
information is 
usually satisfactory 
but the information 
is incorrect only in a 
few situations 
4 
The accuracy of the 
exchanged 
information is very 
good 
How the focal 
company rated 
freshness of the 
information 
they already 
access 
Scale of 1, 11 of them  Scale of 2, 3 of them  
 
Scale of 1, 7 of them  Scale of 2, 1 of 
them  
The scale to 
judge Freshness 
of the 
exchanged 
information 
based on table 
16 metrics 
(How frequently 
the information 
is updated?) 
1 
Less than once a day 
2 
Information is 
updated only when 
the node is asked to 
provide data 
1 
Monthly or less than 
once 
a month 
2 
Information is 
updated only when 
the node is asked 
to provide data  
 
Table 28: The quantity, accuracy and freshness of the exchanged information, Focal Company 
with International Manufacturers 
Semi-quantitative 
judgments 
Transaction/Events Status Information Master Data Operational Data 
The quantity of 
information 
international 
suppliers generate 
13 2 6 3 
How many of those 
generated 
information does the 
focal company access  
12 2 6 3 
How many in 
percentage does the 
focal company access 
92.3% 100% 100% 100% 
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The scale to judge the 
quantity of the 
exchanged 
information based on 
table 14 metrics 
4 
The focal company 
has access to a large 
part of the 
information within 
this category 
4 
The focal company 
has access to a 
large part of the 
information within 
this category 
4 
The focal company 
has access to a 
large part of the 
information within 
this category 
4 
The focal company 
has access to a 
large part of the 
information within 
this category 
How the focal 
company rated 
accuracy of the 
information they 
already access 
Scale of 3, 7 of them 
Scale of 2, 4 of them 
Scale of 4, 1 of them 
Scale of 2, 2 of 
them  
 
Scale of 3, 3 of 
them  
Scale of 4, 3 of 
them  
Scale of 3, 3 of 
them  
The scale to judge 
accuracy of the 
exchanged 
information based on 
table 15  metrics 
3 
The accuracy of the 
exchanged 
information is 
usually satisfactory 
but the information 
is incorrect only in a 
few situations 
2 
The accuracy of the 
exchanged 
information is 
usually satisfactory 
but situations in 
which the 
information is 
incorrect are not 
uncommon  
3 
The accuracy of 
the exchanged 
information is 
usually satisfactory 
but the 
information is 
incorrect only in a 
few situations 
3 
The accuracy of the 
exchanged 
information is 
usually satisfactory, 
but the information is 
incorrect only in a 
few situations 
How the focal 
company rated 
freshness of the 
information they 
already access 
 Scale of 1, 12 of 
them 
Scale of 2, 2 of 
them 
Scale of 2, 6 of 
them  
Scale of 2, 2 of 
them  
The scale to judge 
Freshness of the 
exchanged 
information based on 
table 16  metrics 
(How frequently the 
information is 
updated?) 
1 
Less than once a day 
1 
Information is updated 
only when the node is 
asked to provide data 
2 
Weekly update of 
those information 
2 
Information is 
updated only 
when the node is 
asked to provide 
data  
 
Annex 7.1 
Localization, 
In this case, as all the suppliers in the inbound supply chain are on the first tier list, the localization 
measure is 1(one).  
Significance in terms of value of the goods supplied   
After reviewing the annual purchase report for 2015 of those 11(eleven) items, the cumulative total 
amount of purchase made from the suppliers is listed. The list of suppliers over the year with 
respect to the total amount in sales they have supplied to the focal company is then ranked as 
follows.  
Annex 7.2 
Improving visibility along the Pharmaceutical supply chain: A case study on EPHCSS 
 
Master Thesis                                                                           Molde University College  96 
Criticality estimation  
 
Table 19.013141516 
 
 
 
 
 
 
 
 
 
 
Figure 37: Total purchase by the focal company in 2015, USD  for the selected items 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
13 Nifedipine 40mg substitute  
14 894,618USD-Erytro 250mg(2014 purchase),  6,614,077USD-Amox250/500mg, 2,776,930.43USD –
Cipro5oomgtab  
15 Truskin (Data of 2014)  
16 1 USD =23 ETB  
            Table 29: RDF Suppliers versus focal company Significance Table 
Ranking List of Supplier for RDF 
pharmaceuticals based on the 
purchasing power 
Total amount in USD the 
focal company purchased 
Origin of the 
Supplier  
Items they normally Supplied during 
the year 
             1 A cluster of local suppliers  
10,272,595.826 
 
 
Ethiopia 
Erythromycin 250mg,Amoxicillin 
250mg/500mg,Ciprofloxacilin 500mg 
Tablet  
 
APF 
Epharm 
Cadilla 
East Africa  
2 Truskin Glove Pvt.Ltd 2,426,760.00 India  Surgical gloves sterile latex No. 7.5 
3 Huanggang Hyangzhou 
 
1,586,544.30 China  Gauze Surgical 90cmx100 m mesh 
size 19x15 
4 CSPC Zhongnuo 
Pharmaceutical 
1,557,589.55 China Chloramphenicol Sodium Succinate 
1gm injection 
5 Egyptian International EIPICO 1,316,878.39 Egypt  Insulin zinc suspension 100IU/ml 
injection 
6 GlaxoSmithKline (GSK) 799,848.25 
 
 UK  Nifedipine 40mg, 
Erythromycin (as Stearate)  
500mg tablet 
7 Vins Biopoducts LTD 189,248.20 India T.A.T. 1500IU/ml injection 
8 CSPC Ouyi Phar 90,951.60 China  Cimetidine 200mg/ml, 2ml injection 
 
 
10,272,595.83
2,426,760.00
1,586,544.30
1,557,589.55
1,316,878.39
799,848.25 189,248.20 90,951.60
A cluster of 4 local suppliers Truskin Huanggang
CSPC Zhongnuo EIPICO GSK
Vins CSPC Ouyi
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List of Supplier for RDF 
pharmaceuticals based on 
the purchasing power 
Total amount in 
USD the focal 
company 
purchased 
wsigk, 
significance 
weight of 
each node 
Based on criticality four (4)  response 
scale 
Criticality of the 
item the supplier 
supplies from a 
strategic 
perspective 
(The item is 
critical which 
can’t be 
substituted with 
another item) 
Existence of other 
suppliers for the 
item the supplier 
supplies 
A cluster of local suppliers 10,272,595.826 
 
0.56317771 
 
2  
International Suppliers  
APF 
Epharm 
Cadilla 
East Africa  
Truskin Glove Pvt.Ltd 
 
2,426,760.00 0.13304302 2 International Suppliers 
Huanggang Hyangzhou 
 
1,586,544.30 0.08697961 2 Suzhou Industrial Win 
CSPC Zhongnuo Pharmaceutical 1,557,589.55 0.08539222 2 Macleodes 
Pharmaceutical Limited, 
Egyptian International EIPICO 1,316,878.39 0.07219563 2 International Suppliers 
GlaxoSmithKline (GSK) 799,848.25 
 
0.04385033 2 EIPICO 
Vins Biopoducts LTD 189,248.20 0.01037521 2 Vacsera 
CSPC Ouyi Phar 90,951.60 0.00498627 2 International Suppliers 
Sn, FC – Total purchase amount of 
Focal Company 
18,240,416.12    
Table 30: Overall visibility by Information quantity and quality 
Table 31: Significance weight and criticality measurement estimation 
Improving visibility along the Pharmaceutical supply chain: A case study on EPHCSS 
 
Master Thesis                                                                           Molde University College  98 
 
 
  Overall visibility of type i of information(OV) 
 
 
Total amount of visible 
information of type 
i(TA) 
 
  Node_partial_visibility Jq,j,k(Quantity) 
Nodes  Wstd,k T/E  SI  MD  OD  T/
E 
 S
I 
 M
D 
 O
D 
 
A cluster of 
local suppliers 
0.3189
4 
2.2
8 
0.7
2 
2.8
8 
0.9
1 
2.28 0.7
2 
3.17 0.8
0 
4  4  4  4  
Truskin Glove 
Pvt.Ltd 
 
0.1550
2 
2.2
8 
0.3
5 
2 0.3
1 
2.8
8 
0.4
4 
2.8
8 
0.4
4 
4  4  4  4  
Huanggang 
Hyangzhou 
0.1253
4 
2.2
8 
0.2
8 
2 0.2
5 
2.8
8 
0.3
6 
2.8
8 
0.3
6 
4  4  4  4  
  
  
 
 
Nodes  Wstd,k Node_Vi
s 
Quantit
y  
Total 
amount of 
visible 
information 
Node_Vis 
Accuracy 
Accuracy of 
the overall 
visible 
informatio
n 
Node_Vis 
Freshnes
s 
Freshness of 
the overall 
visible 
information 
Node_Vis 
Quality 
Quality of the 
overall visible 
information 
A cluster 
of local 
suppliers 
0.31
894 
4 1.27576 3.22 1.0269 1.41 0.4497 2.13 0.6793 
Truskin 
Glove 
Pvt.Ltd 
 
0.15
502 
4 0.62008 2.71 0.4201 1.41 0.2185 1.95 0.3022 
Huanggan
g 
Hyangzho
u 
 
0.12
534 
4 0.50136 2.71 0.3396 1.41 0.1767 1.95 0.2444 
CSPC 
Zhongnuo 
Pharmace
utical 
0.12
419 
4 0.49676 2.71 0.3365 1.41 0.1751 1.95 0.2421 
Egyptian 
Internatio
nal EIPICO 
0.11
419 
4 0.45676 2.71 0.3094 1.41 0.1610 1.95 0.2226 
GlaxoSmit
hKline 
(GSK) 
0.08
899 
4 0.35596 2.71 0.2411 1.41 0.1254 1.95 0.1735 
Vins 
Biopoducts 
LTD 
0.04
329 
4 0.17316 2.71 0.1173 1.41 0.0610 1.95 0.0844 
CSPC Ouyi 
Phar 
0.03
001 
4 0.12004 2.71 0.0813 1.41 0.0423 1.95 0.058 
          
          
 4  2.87  1.4099  2.0 
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CSPC Zhongnuo 
Pharmaceutical 
0.1241
9 
2.2
8 
0.2
8 
2 0.2
4 
2.8
8 
0.3
5 
2.8
8 
0.3
5 
4  4  4  4  
Egyptian 
International 
EIPICO 
0.1141
9 
2.2
8 
0.2
6 
2 0.2
2 
2.8
8 
0.3
2 
2.8
8 
0.3
2 
4  4  4  4  
GlaxoSmithKlin
e (GSK) 
0.0889
9 
2.2
8 
0.2
0 
2 0.1
7 
2.8
8 
0.2
5 
2.8
8 
0.2
5 
4  4  4  4  
Vins Biopoducts 
LTD 
0.0432
9 
2.2
8 
0.0
9 
2 0.0
8 
2.8
8 
0.1
2 
2.8
8 
0.1
2 
4  4  4  4  
CSPC Ouyi Phar 0.0300
1 
2.2
8 
0.0
6 
2 0.0
6 
2.8
8 
0.0
8 
2.8
8 
0.0
8 
4  4  4  4  
 2.2
8 
 2.2
8 
 2.6
8 
 2.9
7 
                                             
                                             
4 
 
  Accuracy of the overall visible 
information of type i 
 
Freshness of the overall visible 
information of type i 
 
  Ja,j,k (Accuracy) Jf,j,k (Freshness) 
Nodes Wstd,
k 
T/
E 
 S
I 
 M
D 
 O
D 
 T/
E 
 S
I 
 M
D 
 O
D 
 
A cluster of 
local 
suppliers 
0.318
94 
3 0.9
57 
3 0.9
57 
3 0.9
5 
4 1.2
76 
1 
0.3
1 
2 0.6
38 
1 0.3
1 
2 0.6
3 
Truskin 
Glove 
Pvt.Ltd 
0.155
02 
3 0.4
65 
2 0.3
10 
3 0.4
6 
3 0.4
65 
1 
0.1
5 
1 0.1
55 
2 0.3
1 
2 0.3
1 
Huanggang 
Hyangzhou 
 
0.125
34 
3 0.3
76 
2 0.2
51 
3 0.3
7 
3 0.3
76 
1 
0.1
2 
1 0.1
25 
2 0.2
5 
2 0.2
5 
CSPC 
Zhongnuo 
Pharmaceut
ical 
0.124
19 
3 0.3
73 
2 0.2
48 
3 0.3
7 
3 0.3
73 
1 
0.1
2 
1 0.1
24 
2 0.2
4 
2 0.2
4 
Egyptian 
Internationa
l EIPICO 
0.114
19 
3 0.3
43 
2 0.2
28 
3 0.3
4 
3 0.3
43 
1 
0.1
1 
1 0.1
14 
2 0.2
2 
2 0.2
2 
GlaxoSmith
Kline (GSK) 
0.088
99 
3 0.2
67 
2 0.1
78 
3 0.2
6 
3 0.2
67 
1 0.0
8 
1 0.0
89 
2 0.1
7 
2 0.1
7 
Vins 
Biopoducts 
LTD 
0.043
29 
3 0.1
30 
2 0.0
87 
3 0.1
3 
3 0.1
30 
1 
0.0
4 
1 0.0
43 
2 0.0
8 
2 0.0
8 
CSPC Ouyi 
Phar 
0.030
01 
3 0.0
90 
2 0.0
60 
3 0.0
9 
3 0.0
90 
1 0.0
3 
1 0.0
30 
2 0.0
6 
2 0.0
6 
   3  2.3
19 
 3  3.3
19 
 1  1.3
19 
 1.6
8 
 2.0
0 
Table 32: Overall visibility by type of information 
 
Improving visibility along the Pharmaceutical supply chain: A case study on EPHCSS 
 
Master Thesis                                                                           Molde University College  100 
Annex 7.3  
Table 33: The quantity, accuracy and freshness of exchanged information, program suppliers 
Semi-quantitative 
judgments 
Transaction/Events Status Information Master Data  Operational Data  
The quantity of information 
the international program 
drug supplier generates  
13 2 6 3 
How many of those 
generated information 
does the focal company 
access  
12 2 6 3 
How many in percentage 
does the focal company 
access 
92.3% 100% 100% 100% 
The scale to judge the 
quantity of the exchanged 
information based on table 
7 metrics 
4 
The focal company 
has access to a 
large part of the 
information within 
this category 
4 
The focal 
company has 
access to a large 
part of the 
information 
within this 
category 
4 
The focal 
company has 
access to a large 
part of the 
information 
within this 
category 
4 
The focal 
company has 
access to a large 
part of the 
information 
within this 
category 
How the focal company 
rated accuracy of the 
information they already 
access 
Scale of 4 , 3 of 
them 
Scale of 3 , 9 of 
them 
Scale of 2, 1 of 
them 
Scale of 3, 1 of 
them 
 
Scale of 4, 5 of 
them  
Scale of 3, 1 of 
them  
Scale of 3, 1 of 
them  
Scale of 4, 2 of 
them 
The scale to judge accuracy 
of the exchanged 
information based on table 
8 metrics 
3 
The accuracy of the 
exchanged 
information is 
usually satisfactory, 
and the information 
is incorrect only in a 
few situations 
3 
The accuracy of the 
exchanged 
information is 
usually satisfactory, 
and the information 
is incorrect only in a 
few situations 
3 
The accuracy of 
the exchanged 
information is 
usually 
satisfactory but 
the information is 
incorrect only in a 
few situations 
3 
The accuracy of 
the exchanged 
information is 
usually 
satisfactory but 
the information is 
incorrect only in a 
few situations 
How the focal company 
rated freshness of the 
information they already 
access 
Scale of 1, 12 of 
them  
Scale of 2, 2 of 
them  
 
Scale of 2, 6 of 
them  
Scale of 2, 3 of 
them  
The scale to judge 
Freshness of the exchanged 
information based on table 
9 metrics 
(How frequently the 
information is updated?) 
1 
Less than once a 
day 
2 
Information is 
updated 
only when the node 
is 
asked to provide 
data 
2 
Information is 
updated on a weekly 
basis  
2 
Information is 
updated only 
when the node is 
asked to provide 
data  
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Annex 7.4  
Table 27.0 17  
Table 34: Significance weight and criticality measurement at each node 
Suppliers (n =12) Sk, FC- Focal 
company 
Purchase 
amount, 2015 
USD  
wsigk, 
significance 
weight of 
each node 
Based on criticality four response scale, 
table 11 
Criticality of the 
item the supplier 
supplies from a 
strategic 
perspective 
(The item is critical 
which can’t be 
substituted with 
another item) 
Existence of other 
suppliers for this 
item the supplier 
supplies  
Auro bindo Pharma 
Limited 
44,440,796.93 
 
0.848132768 2 Cipla, Macleods 
Pharmaceuticals, 
Mylan Lab Ltd, 
Hetero 
Strides Arcolab 
Limited 
2,890,337.00 0.055160791 4  
    Macleods 
Pharmaceutical 
Limited 
2,790,644.00 0.053258195 4  
San 
Pharmaceutical 
Industries Ltd 
2,276,618.40 0.043448246 2 CIPLA, Cipla Ltd, 
Mumbai 
Sn, FC – Total 
purchase amount 
of Focal Company 
52,398,396.33    
                                                 
17 Aurobindo ; 29,036,215.23 USD – 3TC/TDF/EFZ , 15,404,581.70 USD –ZDV/3TC/NVP  
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Table 35: Global visibility measure by quantity, quality and type of information for all the suppliers (Local, RDF International and 
Program International 
 
 
 
 
 
 
 
 
 
   
  
 
 
Nodes   Wst
d,k 
Node_
Vis 
Quanti
ty  
Total 
amount of 
visible 
informatio
n 
Node_Vi
s 
Accurac
y 
Accuracy 
of the 
overall 
visible 
informati
on 
Node_V
is 
Freshne
ss 
Freshness 
of the 
overall 
visible 
informatio
n 
Node_Vis 
Quality 
Quality of 
the overall 
visible 
informatio
n 
Cluster 
of 
Progra
m 
Interna
tional 
supplie
rs  
52,398,3
96.3 
 
0.7
4 
 
4 
2.96 
 
3 
2.22 
 
1.68 
1.2432 
 
2.24 
1.6576 
Cluster 
of local 
supplie
rs  
10,272,5
95.826 
 0.1
5 
 
4 
0.6 
 
3.22 
0.483 
 
1.41 
0.2115 
 
2.13 
0.3195 
Cluster 
of RDF 
interna
tional 
supplie
rs 
7,967,82
0.294 
0.1
12 
 
4 
0.448 
 
2.71 
0.3035 
 
1.41 
0.1579
2 
 
1.95 
0.2184 
 70,638,812.45                          
                                                                                      4
3.0065 
 1.6126
2 
 2.1955 
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  Overall visibility of type i of 
information(OV) 
 
 
Total amount of visible 
information of type 
i(TA) 
 
  Node_partial_visibility Jq,j,k(Quantity) 
Nodes  Wstd,
k 
T/E  SI  MD  OD  T/
E 
 S
I 
 M
D 
 O
D 
 
Cluster of 
Program 
Internatio
nal 
suppliers  
0.7
4 
 
 
2.2 
1.6 
 
 
 
2.88 
2.1 
 
 
 
2.88 
2.1 
 
 
 
2.88 
2.1 
        
Cluster of 
local 
suppliers  
0.1
5 
 
2.2 
0.3 
 
2.8
8 
0.4
3 
 
2.2
8 
0.3
4 
 
2.5
1 
0.3
7 
        
Cluster of 
RDF 
internatio
nal 
suppliers 
0.1
12 
 
 
2.2
8 
0.2
5 
 
 
2 
0.2
2 
 
 
2.8
8 
0.3
2 
 
 
2.8
8 
0.3
2 
        
 
 
 2.2
8 
 2.7
8 
 2.7
9 
 2.8
3 
    4    
 
  Accuracy of the overall visible 
information of type i 
 
Freshness of the overall visible 
information of type I 
 
  Ja,j,k (Accuracy) Jf,j,k (Freshness) 
Nodes Wstd,
k 
T/
E 
 S
I 
 M
D 
 O
D 
 T/
E 
 S
I 
 M
D 
 O
D 
 
Cluster of 
Program 
Internationa
l suppliers  
0.74 
 
 
 
 
3 
  
 
 
 
3 
2.22 
 
 
 
 
3 
 
 
 
 
 
3 2.2
2 
 
 
 
 
   1 
  
 
 
 
 
2 
1.48 
 
 
 
 
2 1.4
8 
 
 
 
 
2 
 
Cluster of 
local 
suppliers  0.15 
 
3 
  
3 
0.45 
 
3 
 
 
4 
0.6 
 
  1 
 
 
2 
0.3 
 
1 
0.1
5 
 
2 
 
Cluster of 
RDF 
international 
suppliers 0.112 
 
 
 
3 
  
 
 
2 0.22
4 
 
 
 
3 
 
 
 
 
3 0.3
3 
 
 
 
  1 
 
 
 
 
1 0.11
2 
 
 
 
2 0.2
2 
 
 
 
2 
 
      
 
           
  3   2.89  3  3.15  1  1.89  1.85  2 
 
Table 36: Overall visibility by Information quantity and quality 
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Annex 7.5  
Table 37 : APTS, Hospital activity flow for RDF products 
APTS Activity Flow  
 
Information Flow 
exchanged 
Responsible 
Person 
Forms Used 
Client/patient arrives with a prescription  
 
   
Professional Checks the validity and legitimacy of the 
prescription  
 
Patient personal 
Information; 
     Name, Age and 
Address  
Patient Diagnosis 
    Patient Disease 
Prescription 
Information 
    Drug name, ROA, 
Strength     
    Physician 
Information  
    
 
Evaluator(Pharmacist 
by Profession) 
 
Patient 
Catalog Book  
 If the Drug is stock-out or 
Unavailable 
Stock out  Evaluator 
Coordinator  
Store Man 
DSM (Drug Supply 
M.) 
Personal 
Note 
IFRR 
HMIC  
RRF  
     
Patient/Client 
will be told to 
buy from; 
   Special 
Pharmacy or 
Outside 
Pharmacy 
Product issued from 
Special Pharmacy  
 
Dispenser   
 Stocked out 
//unavailable 
items are 
reported to 
unit 
coordinator 
 
 
 
Stocked out list  Evaluator  Personal 
Note  
 Stocked out 
Product 
request Order 
is sent to 
store-man  
 Stocked out product 
list request  
Coordinator  IFRR (Internal 
Facility 
Requisition 
and 
Reporting 
format) 
 If product is 
in store, 
store-man 
refills the 
pharmacy 
 Pharmacy outlet 
stock refill 
Warehouse stock 
issued 
Store-man  
Coordinator  
Bin-card 
Stock-card  
Model-20 
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  If product is 
also stocked 
out in store, 
purchase 
order list is 
generated 
and sent to 
PFSA  
Purchase order 
generated  
Purchase order sent  
DSM(Drug Supply 
Manager) 
CCO(Chief Clinical 
Officer) 
CEO (Chief Executive 
Officer) 
RRF (Report 
and 
Requisition 
format) 
Formal 
Letter  
Product 
Purchase 
format  
  If product is 
available in 
PFSA, 
hospital will 
be filled with 
stock.  
Store Product receive  
Product Stock status 
updated 
DSM  
Store-man  
Invoice  
Model-19  
Bin-card  
Stock-card  
 
 
 Payment for 
PFSA 
generated 
and 
completed  
Payment initiated  
Payment Completed  
Finance Accountant  Invoice  
Model-19  
Payment 
Voucher  
 If product is 
not available 
in PFSA, 
Purchase 
order is 
redirected to 
Private 
Suppliers   
 PFSA Stock out  
 
PFSA Distribution 
Officer  
Stock-out list 
paper  
If the drug is in Stock,     
 Client/Patient 
Pays Cash or 
get 
registered for 
Credit 
payment 
 Cash paying Client  
Credit Client  
Casher  Cash Receipt 
Credit 
Registry  
If Client is a 
‘free’ user, 
no need of 
passing 
through the 
casher 
  Free Patient status  Evaluator  Free Patients 
Registry Book 
Client /Patient Receives the 
Medicine  
 Medicine Issued  
Drug Stock Status 
Updated 
Dispenser  
     
 Patient/Client 
will get a 
detailed 
counselling 
or 
Orientation  
  Counselor   
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Prescription Archived 
And Patient/Client Exits  
 Transaction 
Completed 
Data Clerk Internal 
prescription 
archiving 
folders 
At the end of the day, 
Document cross-checking is 
conducted  
 Correctly 
crosschecked  
Document 
mismatched  
Accountant  
Auditor  
Patient 
Catalog Book  
Prescription 
Archive  
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Annex 7.6  
Table 38 : Measuring the quantity and quality of information accessed by the focal company 
(RDF/Hospitals) 
Semi-quantitative 
judgments 
Transaction/Events Status 
Information 
Master Data  Operational Data  
The quantity of information 
the hospital generates  
12 6 7 2 
How many of those 
generated information 
does the focal company 
access  
10 6 2 2 
How many in percentage 
does the focal company 
access 
83.3 %  100 % 28.5 %  100% 
The scale to judge the 
quantity of the exchanged 
information based on table 
8 metrics 
3 
The focal company 
has access to a 
large part (more 
than 75 per cent) 
of the information 
within this 
category 
4 
The focal 
company has 
access to a large 
part (more than 
75 per cent) of 
the information 
within this 
category  
2 
The focal company 
has partial access 
(between 25 and 50 
per cent) to the 
information 
with this category  
4 
The focal company 
has access to a 
large part (more 
than 75 per cent) of 
the information 
within this category 
How the focal company 
rated accuracy of the 
information they already 
access 
Scale of 3 , 10 of 
them 
 
Scale of 2, 6 of 
them 
 
Scale of 3, 1 of 
them  
Scale of 2, 1 of 
them  
 
Scale of 2, 2 of 
them 
 
The scale to judge accuracy 
of the exchanged 
information based on table 
9 metrics 
3 
The accuracy of 
the exchanged 
information is 
usually 
satisfactory but 
the information is 
incorrect only in a 
few situations 
2 
The accuracy of 
the exchanged 
information is 
usually 
satisfactory, 
but situations in 
which the 
information is 
incorrect are not 
uncommon 
2 
The accuracy of 
the exchanged 
information is 
usually 
satisfactory, 
but situations in 
which the 
information is 
incorrect are not 
uncommon 
2 
The accuracy of the 
exchanged 
information is 
usually satisfactory, 
but situations in 
which the 
information is 
incorrect are not 
uncommon 
How the focal company 
rated freshness of the 
information they already 
access 
Scale of 1, 10 of 
them  
Scale of 1, 6 of 
them  
 
 
Scale of 1, 1 of 
them  
Scale of 3, 1 of 
them 
Scale of 2, 1 of 
them 
The scale to judge 
Freshness of the exchanged 
information based on table 
10 metrics 
(How frequently the 
information is updated?) 
1 
Less than once a day 
1 
unsatisfactory 
1 
Monthly or less than 
once 
a month. The 
information is 
gathered only when 
the focal company is 
makes a request and 
contacts the focal 
company.  
2 
Information is 
updated only when 
the node is asked 
to provide data. 
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Annex 7.7  
Table 39:  IPLS, Hospital activity flow for Program products 
                 IPLS Activity Flow  Inform
ation 
Flow 
exchan
ged  
Respon
sible 
Person 
Forms 
Used 
 
ART  
(-3TC 300mg/TDF 
300mg/EFZ 600mg Tab,30  
-AZT 300mg/3TC  
150mg/NVP 200mg Tab, 
60) 
   
Patient/
Client 
comes in 
every 60 
days 
New 
patie
nt 
may 
be 
referr
ed at 
anyti
me  
Patient 
/Client 
on an 
emerg
ency 
case 
can 
also 
appear 
at any 
time  
-Patient 
Registry 
is 
updated  
-Drug 
Informa
tion 
-
Treatme
nt 
Progress 
Informa
tion  
Pharma
cist/ 
Dispens
er  
EDT 
(Electr
onic 
Dispen
sing 
Tool)   
 
 If stock is in 
store  
  
 Patient/Clie
nt is refilled 
or Issued 
Regimen 
Medicin
e first 
time 
issued 
Medicin
e 
Refilled   
Pharma
cist/ 
Dispens
er 
If stock is 
unavailable, 
Emergency 
request is 
initiated  
 ART 
product 
Stock 
out  
Program 
product 
Stock 
out  
Emerge
ncy 
product 
request  
 
Pharma
cist/ 
Dispens
er  
Produc
t 
reques
t 
format 
Formal 
Letter  
Emergency 
product 
 Emerge
ncy 
Stock 
Store-
Man  
STV(St
ock 
Transf
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request 
fulfilled  
Update
d  
Dispens
er  
er 
Vouch
er)  
Model
-19  
Regular Product request is 
initiated every 2 months  
Weekly 
inter 
facility 
request 
Monthly 
outer 
facility 
product 
requisiti
on 
 
Pharma
cist/ 
Dispens
er   
Store 
Man 
DSM  
CEO 
IFRR 
(Intern
al 
Facility 
Report
ing 
Forma
t) 
RRF 
4 months of stock based on 
the RRF sent is received 
from PFSA  
Monthly 
Stock 
refilled   
 
Store-
Man  
PFSA 
Delivere
r 
EDT  
HCMIS 
STV  
Model
-19  
Stock 
card 
Bin 
card 
 TB 
RHZE of 12x28, 
Kit 
(DOT) 
    
 Contin
uing 
Patien
t 
comes 
every 
day-
for 
refill 
for 2 
mnth   
 -Patient 
Registry 
is 
updated  
-Drug 
Informa
tion 
-
Treatme
nt 
Progress 
Informa
tion  
Pharma
cist/ 
Dispens
er  
Patien
t and 
Drug 
registr
y 
catalo
g  
New 
Patien
t 
starts 
treat
ment   
  
The rest processes go the same as ART  
 Malaria  
Artemether 
+ 
lumefanthri
ne( 20 
  -Patient 
Registry 
is 
updated  
Pharma
cist/ 
Dispens
er  
Patien
t and 
Drug 
registr
y 
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+120) Mg 
6X4, 30 
-Drug 
Informa
tion 
-
Treatme
nt 
Progress 
Informa
tion  
catalo
g  
New 
patient 
diagnosed 
with 
falciparum 
comes in  
     
The rest processes go the same as ART 
       
Family 
Planning 
Medroxyproge
sterone 
acetate 
150mg/ml in 
1ml, Vial  
      
A client 
comes in 
every 
three 
months 
A 
new 
clie
nt 
com
es 
in  
   -Patient 
Registry 
is 
updated  
-Drug 
Informati
on 
-
Treatme
nt 
Progress 
Informati
on  
Pharmaci
st/ 
Dispense
r  
Patient 
and 
Drug 
registry 
catalog  
The rest processes go the same as ART 
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Annex 7.8 
 Table 40: Measuring the quantity and quality of information accessed by the focal company (Program/Hospitals) 
 
Semi-quantitative judgments Transaction/Events Status Information Master Data  Operational Data  
The quantity of information 
the hospital generates  
7 7 6 4 
How many of those generated 
information does the focal 
company access  
7 7 5 4 
How many in percentage does 
the focal company access 
100% 100% 83.3% 100% 
The scale to judge the quantity 
of the exchanged information 
based on table 8 metrics 
4 
The focal company has 
access to a large part 
(more than 75 per 
cent) of the 
information 
within this category 
4 
The focal company has 
access to a large part 
(more than 75 per cent) 
of the information 
within this category  
4 
The focal company 
has access to a large 
part (more than 75 
per cent) of the 
information 
within this category 
4 
The focal company has 
access to a large part 
(more than 75 per 
cent) of the 
information 
within this category 
How the focal company rated 
accuracy of the information 
they already access 
Scale of 2 , 2 of them 
Scale of 3 , 3 of them 
Scale of 4 , 2 of them 
 
Scale of 3, 5 of them 
Scale of 4, 2 of them 
 
Scale of 2, 2 of them  
Scale of 3, 2 of them  
 
Scale of 3, 2 of them 
Scale of 1, 4 of them 
 
 
The scale to judge accuracy of 
the exchanged information 
based on table 9 metrics 
3 
The accuracy of the 
exchanged information 
is usually satisfactory 
but the information is 
incorrect only in a few 
situations 
3 
The accuracy of the 
exchanged information 
is usually satisfactory 
but the information is 
incorrect only in a few 
situations 
2 
The accuracy of the 
exchanged 
information is 
usually satisfactory, 
but situations in 
which the 
information is 
incorrect are not 
uncommon 
2 
The accuracy of the 
exchanged information 
is usually satisfactory, 
but situations in which 
the information is 
incorrect are not 
uncommon 
How the focal company rated 
freshness of the information 
they already access 
Scale of 1, 4 of them 
Scale of 4, 2 of them  
Scale of 2, 1 of them 
Scale of 2, 4 of them 
Scale of 4, 2 of them  
Scale of 3, 1 of them  
 
Scale of 3, 2 of them 
Scale of 1, 4 of them 
Scale of 2, 2 of them 
Scale of 4, 2 of them 
The scale to judge Freshness 
of the exchanged information 
based on table 10 metrics 
(How frequently the 
information is updated?) 
1 
Less than once a day 
3 
In some cases 
information is updated 
only when the node is 
asked to provide data 
1 
Monthly or less than 
once 
a month. The 
information is gathered 
only when the focal 
company is makes a 
request and contacts 
the focal company.  
2 
Information is updated 
only when the node is 
asked to provide data. 
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Annex 7.9  
Product availability table survey for PFSA hubs  
TABLE DESCRIPTION  
Products specified from 1-11 are under the RDF while those from 12-16 are under PROGRAM  
Column:  
1. Name of all authorized products  
2. Unit of count for the product Note 
3. Unit cost for the product Note 
Columns 1, 2 and 3 will be filled out before questionnaires are printed for the survey.  
4. Is product available in stock, answer Y for yes or N for no.  
5. What is the expiry date of the respective product in stock? 
6. If product is available in stock, what is the current updated balance reading from the bin-
card or HCMIS? 
7. Have you experienced any stock outs within most recent of 6 months (from 1/10/2015 – 
1/03/2016) 
8. If any stock-outs within the full year, can you remember the number of stock-out events 
happened 
9. Total number of days stocked out  
10. Total issued (Most recent 6 months) 
11. Is there any expired product available in stock? If any, how many in units? 
12. What is the total average monthly consumption of the product by the lower level (Lower 
level for Main hub are the regional hubs, Lower level for the regional hubs are health 
facilities)  
13. What is your; Maximum and maximum months of stock? If you don’t have any apply any 
such inventory policy, do you think you are overstocked of this product?  
 
Note: For any product that experienced a stock-out in the last six months, please note 
reasons (by product). 
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 Product Units of 
Count  
 
Unit Cost Availa
ble in 
Stock? 
(Y/N) 
Product 
Expiry 
Date  
 
Balance 
( Bin-card 
or 
HCMIS)  
Stock-out 
most 
recent 6 
months 
(Y/N) 
Number 
of stock-
outs 
within the 
year 
Total 
number 
of days 
stocked 
out  
Total issued 
(Most recent 
6 months) 
Availability 
of expired 
product 
(Y/N) 
Product 
consumption by 
lower level 
(average 
monthly) 
Stock policy  
( Min, Max )  
 1 2 3 4 5 6 7 8 9 10 11 12 13 
1 Nifedipine 20mg tablet  20x10            
2 Insulin zinc suspension 100IU/ml 
injection  
Vial             
3 Chloramphenicol Sodium Succinate 1gm 
injection  
Ampoule            
4 Erythromycin (as Stearate) tablet - 250 
mg, 500mg  
100x10            
5 Gauze Surgical 90cmx100 m mesh size 
19x15  
Roll            
6 Surgical gloves sterile latex No. 7.5  100            
7 T.A.T. 1500IU/ml injection  Ampoule            
8 Cimetidine 200mg/ml, 2ml injection Vial            
9 Cotrimoxazol Suspension 240mg/5ml  240mg/5ml            
10 Amoxicillin 250mg,500mg tablet 100x10             
11 Ciprofloxacin 500mg Tablet  100x10            
12 Lamivudine 300mg/Tenofovir 
300mg/Efavirenz 600mg Tablet 
Bottle             
13 Zidovudine 300mg/Lamivudine 
150mg/Nevirapine 200mg Tablet 
Bottle            
14 RHZE (150mg+75mg+400mg+275mg) , 
RH- (150mg+75mg)  
24x28            
15 Artemether + lumefanthrine ( 20 
+120)mg 
30            
16 Medroxyprogesterone acetate 150mg/ml 
injection  
Vial             
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Annex 8.0 
SCV solution scorecard grading metrics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.0 Sensitivity Grading  
 
2.0 Accessibility Grading  
 
  3.0 Intelligence Grading  
 
 4.0 Decision relevance Grading  
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